We’ve been in Boston with the Venture Leaders Biotech teams - a selection of the most promising Swiss based biotech startups attending a global business development and investor roadshow.
#cancer #oncology #radiotherapy #darpin #radiodarpin #investing
www.linkedin.com/feed/update/urn:li:activity:734433912095…
Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. More on Wikipedia
-
Molecular Partners
@MolecularPrtnrs
-
Molecular Partners
@MolecularPrtnrs
We and our strategic partner Orano Med are pleased to announce the debut of MP0726, our Radio-DARPin candidate targeting mesothelin (MSLN) - and to present preclinical data at SNMMI tomorrow.
#cancer #oncology #radiotherapy #darpin #radiodarpin
investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
We had a great time this weekend taking part in the Sola Run Zurich! Our 14-member running team tackled a challenging 115 km course.
#solastafette #teamspirit #communityengagement #companypride #zurichevents #swisssports
www.linkedin.com/feed/update/urn:li:activity:733161236696… -
Molecular Partners
@MolecularPrtnrs
We had the privilege to present not just once, but twice, at the 2025 PEGS Boston Summit.
#pegsbostonsummit #biotech #darpin #radiodarpin #innovation #science
www.linkedin.com/posts/molecular-partners-ag-zurich-switz… -
Molecular Partners
@MolecularPrtnrs
Swiss Biotech Day 2025 was a great opportunity to connect with thought-leaders, partners, investors, media and other stakeholders and share insights.
#swissbiotechday #sbd2025 #biotech #conference #investing #radiotherapy #darpin #radiodarpin
www.linkedin.com/feed/update/urn:li:activity:732762309695… -
Molecular Partners
@MolecularPrtnrs
We’re looking forward to hosting and participating in a panel discussion on Radioligand therapies at Swiss Biotech Day, on Tuesday May 6 at 15:00-15:45.
👉 www.linkedin.com/posts/molecular-partners-ag-zurich-switz…
#swissbiotechday #sbd2025 #biotech #conference #investing #radiotherapy #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
We have a lot going on today at Swiss Biotech Day! Check out the details below.
#swissbiotechday #sbd2025 #networking #biotech #conference #investing #radiotherapy #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
We had the pleasure of hosting 55 talented biotechnology students from ZHAW, who are exploring future career opportunities.
www.linkedin.com/posts/molecular-partners-ag-zurich-switz…
#biotech #careers #students #innovation #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
The DARPin modality underpins our Switch-DARPin pipeline, through which we are opening doors to treat diseases with precision and efficiency. We presented on it at #aacr2025.
investors.molecularpartners.com/scientific
#biotech #innovation #cancer #darpin #nextgenmedicine -
Molecular Partners
@MolecularPrtnrs
On AML World Awareness Day, we stand united to shine a light on Acute Myeloid Leukemia (AML), a challenging and aggressive form of blood cancer.
👉 www.linkedin.com/posts/molecular-partners-ag-zurich-switz… -
Molecular Partners
@MolecularPrtnrs
We were delighted to welcome shareholders to our Annual General Meeting (AGM) today. All resolutions were approved.
👉investors.molecularpartners.com/news-releases/news-releas…
#agm2025 #biotech #innovation #shareholdersupport #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
Molecular Partners will be attending Swiss Biotech Day on May 6, 2025! We are a sponsor of this event, which is a fantastic opportunity to connect.
👉www.linkedin.com/feed/update/urn:li:activity:731783411915…
#swissbiotechday #sbd2025 #networking #biotech #conference #investing #radiotherapy #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
Our Radio-#darpin platform delivers radioactive payloads directly to solid tumors. Don’t miss our presentation on targeting mesothelin (MSLN) at #aacr2025!
👉 www.linkedin.com/feed/update/urn:li:share:731568892656684…
#biotech #innovation #cancer #nextgenmedicine -
Molecular Partners
@MolecularPrtnrs
Molecular Partners’ exclusive strategic partnership with @OranoMed on Radio-DARPins is particularly powerful. Find out more and look out for our upcoming presentation at #aacr2025.
👉 www.linkedin.com/posts/molecular-partners-ag-zurich-switz…
#radiotherapy #radiodarpins #nextgenmedicine #biotech #cancer -
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz will be taking part in a panel discussion on radiopharmaceuticals at the Van Lanschot Kempen Life Sciences Conference, on April 3 at 10:30am CET.
#cancer #oncology #biotech #investing #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
Join us in Chicago at the American Association for Cancer Research (AACR) Annual Meeting 2025, from April 25-30!
👉investors.molecularpartners.com/news-releases/news-releas…
#cancer #oncology #aacr2025 #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
A big thank you to everyone who attended and engaged with us at the Fourth Transatlantic Exchange in Oncology this week – particularly around our presentation on scaling up the Radio-DARPin platform with Orano Med.
#investing #conferences #oncology #cancer #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
We’re looking forward to presenting at the Fourth Transatlantic Exchange in Oncology, which takes place in Paris on Wednesday March 19.
👉events.medscapelive.org/website/82041/
#investing #conferences #oncology #cancer #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
We’ve just released our financial results and Annual Report for 2024!
👉investors.molecularpartners.com/news-releases/news-releas…
#financials #financialresults #ar2024 #oncology #cancer #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
Continuing our women in STEM series, today we are spotlighting Joanna Robinson and what drives her passion for oncology research.
👉www.linkedin.com/feed/update/urn:li:activity:730264915296…
#womeninstem #cancer #iwd2025 #internationaldayofwomenandgirlsinscience -
Molecular Partners
@MolecularPrtnrs
Thanks to In Vivo for the interesting article on our expanded Radio-DARPin partnership with Orano Med. Click below for more (subscription).
insights.citeline.com/in-vivo/innovation/orano-med-and-mo…
#partnership #oncology #cancer #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
Our SVP of Research & Technology Daniel Steiner was in Boston this week to present at the TRP Target Selection and Drug Design Summit.
👉www.linkedin.com/feed/update/urn:li:share:730228666194040…
#oncology #cancer #cancerresearch #darpin -
Molecular Partners
@MolecularPrtnrs
Some dates for your diary! 2024 results on March 6 and conference call March 7 – plus two upcoming fireside chats.
👉 www.linkedin.com/feed/update/urn:li:share:730120105816748…
#financialresults #investing #conferences #cancer -
Molecular Partners
@MolecularPrtnrs
Molecular Partners is featured in Scrip Asks on the future of biopharma in 2025!
👉insights.citeline.com/scrip/scrip-asks/scrip-asks-what-do…
#oncology #cancer #darpin #radiodarpin -
Molecular Partners
@MolecularPrtnrs
We’re highlighting the voices of women in STEM who are driving innovation and impact – meet our colleague Alienor Auge.
👉www.linkedin.com/feed/update/urn:li:activity:729827313042…
#womeninstem #cancer #iwd2025 #internationaldayofwomenandgirlsinscience -
Molecular Partners
@MolecularPrtnrs
Next week our SVP of Research & Technology Daniel Steiner who will be presenting at the TRP Target Selection and Drug Design Summit - on Weds Feb 26 at 10:10am ET.
👉www.linkedin.com/feed/update/urn:li:activity:729756405864…
#oncology #cancer #cancerresearch -
Molecular Partners
@MolecularPrtnrs
International Day of Women and Girls in Science is a moment to celebrate the brilliant females who are driving innovation and discovery.
👉www.linkedin.com/feed/update/urn:li:activity:729502415745…
#womeninscience #equityinstem #internationaldayofwomenandgirlsinscience -
Molecular Partners
@MolecularPrtnrs
Thanks to @Labiotech for this very interesting article on key oncology trends in 2025 – featuring Molecular Partners.
👉www.labiotech.eu/in-depth/oncology-trends-2025/ -
Molecular Partners
@MolecularPrtnrs
The team at Molecular Partners is committed to making a difference.
#worldcancerday is a moment to reflect on those efforts.
#cancer #cancerresearch -
Molecular Partners
@MolecularPrtnrs
With the 43rd Annual J.P. Morgan Healthcare Conference behind us, we wanted to share highlights of our week.
👉www.linkedin.com/feed/update/urn:li:activity:729032150708…
#radiopharmaceuticals #immunooncology #darpins #cancerresearch #investing -
Molecular Partners
@MolecularPrtnrs
We’re at the 43rd Annual JP Morgan Healthcare Conference! CEO Patrick Amstutz is presenting January 15 at 9:00am PT (6:00pm CET).
👉 www.linkedin.com/posts/molecular-partners-ag-zurich-switz…
#radiopharmaceuticals #immunooncology #darpins #cancerresearch #investing -
Molecular Partners
@MolecularPrtnrs
Molecular Partners shares 2025 milestones & updates ahead of the 43rd J.P. Morgan Healthcare Conference.
👉 investors.molecularpartners.com/news-releases/news-releas…
#radiopharmaceuticals #immunooncology #darpins #cancerresearch #investing -
Molecular Partners
@MolecularPrtnrs
We have today expanded our strategic collaboration with Orano Med – it now includes the co-development of an additional six targeted alpha therapeutics candidates.
👉 investors.molecularpartners.com/news-releases/news-releas…
#oncology #cancer #cancerresearch #immunooncology #partnership -
Molecular Partners
@MolecularPrtnrs
We are wishing our team, patients, and loved ones a happy holiday season!
-
Molecular Partners
@MolecularPrtnrs
Find us at #jpm25 & the #baaderhalvea Swiss Equities Conference next month.
Hear from CEO Patrick Amstutz or COO Alexander Zurcher as they speak to our recent progress and upcoming plans. Reach out to schedule a meeting.
Details: investors.molecularpartners.com/news-releases/news-releas…
@jpmorgan @Baader_Bank -
Molecular Partners
@MolecularPrtnrs
At #ash2024, we will present data from 2 programs:
➡️ MP0533: Demonstrated safe, dosing optimized via protocol amendment
➡️ MP0621: Preclinically validated as a next-gen conditioning agent for stem cell transplantation
Details: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
We’re looking forward to presenting at the 6th Annual Targeted Radiopharmaceuticals Summit Europe.
Hear from SVP, Research & Technology Daniel Steiner as he overviews our DLL3-targeting #radiodarpin therapeutic candidate, MP0712, which is in co-development with @OranoMed.
#trp -
Molecular Partners
@MolecularPrtnrs
This #nationalfutureday, we were thrilled to partner with Life Science Cares CH & @CaritasSwiss to welcome a group of children to our Zürich HQ. We always appreciate opportunities to share our passion for science & play a role in inspiring the future #stem workforce. #zukunftstag
-
Molecular Partners
@MolecularPrtnrs
#icymi: We – alongside our partners at @OranoMed – were in Hamburg, Germany at #eanm24 last month to present the latest preclinical data supporting our DLL3-targeting #radiodarpin Therapeutic (#rdt), MP0712.
Details: investors.molecularpartners.com/news-releases/news-releas…
#cancerresearch #radiopharmaceuticals -
Molecular Partners
@MolecularPrtnrs
We’re on the ground in Houston, TX for #sitc24! On Saturday, we’ll be presenting additional analyses of MP0317, our FAP x CD40 localized agonist, & introducing our novel CD3 Switch-DARPin as next-gen T cell engager for solid tumors.
Details: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Molecular Partners will be sharing two updates at #ash24, including Phase 1/2a data on MP0533 and preclinical MP0621 data on our Switch-DARPin candidate as a next-gen conditioning regimen for HSCT.
Learn more: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
This week at #pegseurope our Senior Director of Research Andreas Bosshart, will be presenting recent advances in our #radiodarpin therapeutic (RDT) development.
Check out his presentation in person on Nov 6 at 9 am CET!
#radiopharmaceuticals #darpins -
Molecular Partners
@MolecularPrtnrs
Today we announced our Q3 2024 corporate highlights and unaudited financial results.
Learn more about our progress and plans for the rest of the year here: investors.molecularpartners.com/news-releases/news-releas…
$MOLN #darpins #radiodarpins #radiopharma #cancerresearch #swissbiotech -
Molecular Partners
@MolecularPrtnrs
Today we announced our strengthened co-development agreement with @OranoMed to develop and market 212Pb-based #radiodarpin Therapeutics for the treatment of #cancer. The agreement now targets four programs, including our first program MP0712.
Details: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Today at #eanm24, we're presenting additional positive preclinical data supporting our DLL3-targeting #radiodarpin Therapeutic (RDT) candidate MP0712, which is in co-development with @OranoMed. Stop by our presentation between 8-9:30 AM CET! Learn more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Our MP0317 #darpin is designed to activate immune cells specifically within the tumor microenvironment (TME).
Learn what our Phase 1 biomarker analyses reveal about its impact on the TME at #sitc24 and watch the video below to see how this CD40 agonist is designed to work.This media couldn't be displayed. See it on the original post. -
Molecular Partners
@MolecularPrtnrs
Join us in celebrating David Baker, Demis Hassabis, and John M. Jumper on their Nobel Prize in Chemistry. Our work to develop a new class of #darpin therapeutics for patients is indebted to their advances in protein design and prediction.
The Nobel Prize
@NobelPrize
BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 #nobelprize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.” -
Molecular Partners
@MolecularPrtnrs
We’re looking forward to introducing our CD3 Switch-DARPin for targeted and conditional immune cell activation & presenting on our MP0317 program for advanced solid tumors at #sitc24 on Nov 9. Stop by our posters to learn more and say hi!
Details: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Our team recently had the pleasure of sharing our work with a group of Life Science students from the @UChicago, who were full of questions after touring our facilities, learning more about #darpins & getting a taste of what it is like to work on a novel drug class.
-
Molecular Partners
@MolecularPrtnrs
We will be at #eanm2024, presenting on our 212Pb-labeled #radiodarpin therapeutic (RDT) candidate, MP0712, in co-development with @OranoMed for patients with small cell lung cancer.
Join us and learn more: investors.molecularpartners.com/news-releases/news-releas…
@EANM_NucMed -
Molecular Partners
@MolecularPrtnrs
Join MP’s Vaia Stavropoulou, Ph.D., at Biomarkers Europe 2024 to learn how we are using biomarkers to accelerate clinical development, as illustrated by our phase 1 study of MP0317, our #darpin therapeutic for advanced solid tumors.
-
Molecular Partners
@MolecularPrtnrs
Join us this #worldcancerresearchday as we recognize the efforts of all folks working towards a future without cancer, including our great team, who focus on some of the toughest challenges in medicine.
Learn more about our #oncology pipeline: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
How would we describe Molecular Partners in one word? Pioneers.
We are the inventors and developers of #darpin therapeutics – an entirely new class of custom-built drugs – with the goal of transforming the lives of patients with serious diseases.
#cancerresearch #oncology -
Molecular Partners
@MolecularPrtnrs
~1.24M #bloodcancer cases occur globally each year.
#bloodcancerawarenessmonth serves to raise awareness of patients with this group of diseases and we’re dedicated to making a difference.
More on our #darpin therapy for #aml, MP0533: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Members of our leadership will attend the @UBS Best of Switzerland Conference next week. Get in touch to meet us: investors.molecularpartners.com/ir-resources/contact-ir #swissbiotech
-
Molecular Partners
@MolecularPrtnrs
Next week at #cicon24, MP's Ana Maria Florescu, PhD, will present positive translational data from the phase 1 study of our #darpin therapeutic MP0317. Stop by our poster to learn how MP0317 treatment leads to profound transcriptional changes in the tumor microenvironment.
-
Molecular Partners
@MolecularPrtnrs
We’re incredibly pleased to announce that Philippe Legenne was appointed as CMO at Molecular Partners, after serving as acting CMO for the past year.
More in our H1 2024 report: investors.molecularpartners.com/news-releases/news-releas…
$MOLN #darpins -
Molecular Partners
@MolecularPrtnrs
Today we announced our corporate highlights and financials for the first half of 2024. Join us as we discuss our results on our conference call tomorrow, Aug 27 at 2:00 pm CET (8:00 am EDT).
Details: investors.molecularpartners.com/news-releases/news-releas…
$MOLN #darpins #radiodarpins -
Molecular Partners
@MolecularPrtnrs
We're looking forward to announcing our corporate highlights & financial results for the first half of 2024 on Mon. Dial 1-884-763-8274 (or +41-44-575-0267 for folks in Switzerland) to join the conference call at 2 pm CET (8 am EDT) on Tues, Aug 27.
$MOLN #darpins #radiodarpins -
Molecular Partners
@MolecularPrtnrs
MP0533 is designed to deliver better clearance of AML cells with less risk to healthy cells: a clear match for the medical need in many #aml patients today.
For more on this tetra-specific #cancer therapy in development, see www.molecularpartners.com/pipeline/
#biotech #darpins -
Molecular Partners
@MolecularPrtnrs
#dyk biotech & pharma contribute ~40% to Switzerland’s exports? Today we celebrate #swissnationalday and all the amazing things about Switzerland!
More: www.swissbiotech.org/industry/
#swissbiotech -
Molecular Partners
@MolecularPrtnrs
Summer is in full swing here in Zürich! At our annual summer social, our team was able to soak up the sun, enjoy each other’s company & celebrate colleagues who have been with MP for 15 years.
We’re feeling ready to tackle the second half of 2024!
www.molecularpartners.com/careers/ -
Molecular Partners
@MolecularPrtnrs
We’re a clinical-stage #biotech pioneering #darpin therapeutics for patients. Through our leadership, alongside our partners, we’ve developed 7 clinical-stage DARPin candidates across several therapeutic areas, treating >2500 patients.
Learn more: molecularpart.wpenginepowered.com/wp-content/uploads/mp_f… -
Molecular Partners
@MolecularPrtnrs
Riding our bikes to work helps us get into high gear at the office! Over the past two months, we’ve enjoyed taking part in the #biketowork challenge. Thanks to all participants, who together biked an impressive 8803 km!
-
Molecular Partners
@MolecularPrtnrs
We’re at @GordonConf Radionuclide Theranostics for the Management of Cancer to talk about our first #radiodarpin candidate, in co-development w/ @OranoMed. Join Michael Stumpp & Alessandra Villa to hear our progress.
View the full conference agenda here: www.grc.org/radionuclide-theranostics-for-the-management-… -
Molecular Partners
@MolecularPrtnrs
Wishing our U.S.-based teammates, friends and families a very happy Independence Day!
-
Molecular Partners
@MolecularPrtnrs
#icymi Molecular Partners had a busy month attending #asco, #bio2024, #snmmi and #eha2024!
Catch up on updates across our pipeline by checking out our recent presentations #radiodarpin #switchdarpin: investors.molecularpartners.com/scientific -
Molecular Partners
@MolecularPrtnrs
We’re proud to be part of R&D community that makes #cancerimmunotherapymonth possible. Our MP0317 and MP0533 programs maximize the versatility of #darpins to create novel therapeutics for cancer patients worldwide.
Learn more: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Happy #pridemonth from Molecular Partners! We are committed to fostering a safe and inclusive culture where everyone can come to work as their true self.
#pride2024 -
Molecular Partners
@MolecularPrtnrs
Today, our EVP Projects Michael Stumpp will be participating in a virtual fireside chat at the TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit.
Tune in to the webcast at 10:40 AM ET: wsw.com/webcast/cowen159/register.aspx?conf=cowen159&page…
#radiopharmaceuticals
@TDBank_US -
Molecular Partners
@MolecularPrtnrs
We are excited to share an update on MP0621, our cKIT #switchdarpin program at #eha2024.
Learn more about this program from team members Alexander Link and Anne Goubier at our poster tonight at 6 PM CET. More: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Today at #snmmi, our Sr. Director Radiotherapeutics will present promising preclinical data, demonstrating positive biodistribution, antitumor efficacy & tolerability by MP0712, which we co-developed with @OranoMed.
More: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
We are looking forward to sharing our latest advances in #rdt at #snmmi. Join us for our DLL3 program update and a panel discussion with our acting CMO on driving molecular imaging innovation with “FAPI.”
More: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
MP Lead Generation Director & Sr Director will be presenting at Antibody Engineering & Therapeutics Europe.
Join them to learn about next-gen #darpin based protein therapeutics & our #switchdarpin technology.
More: informaconnect.com/antibody-engineering-europe/agenda/1/
@AntibodyEngIC -
Molecular Partners
@MolecularPrtnrs
Today is #worldbicycleday. For the past month, our team has been participating in the #biketowork challenge, the largest bike & health promotion campaign in Switzerland. Help us cheer our team on as we continue this challenge through June!
-
Molecular Partners
@MolecularPrtnrs
We are on the ground in the Windy City for #asco24, where we will be sharing the full clinical Phase 1 data from our MP0317 program for advanced solid tumors.
If you will be at the conference, don’t miss our poster presentation tomorrow at 9:00 AM CT. -
Molecular Partners
@MolecularPrtnrs
Today, our CEO Patrick Amstutz joins a panel focused on #radiopharmaceuticals at the Boston Radionuclide Theranostics Forum in Boston, MA. Alongside other leading innovators, he will discuss the future of the field, challenges & opportunities.
#radioligands #radiodarpins -
Molecular Partners
@MolecularPrtnrs
Next week, we'll be in San Diego for #bio2024. MP SVP Business Dev Michael Pitzner, VP Business Dev Rekha Paleyanda and SVP Research & Early Dev Anne Goubier are looking forward to attending the conference and meeting with potential new partners.
Reach out if you'll be there! -
Molecular Partners
@MolecularPrtnrs
We look forward to sharing full clinical Phase 1 data from our MP0317 program for advanced solid tumors next week at #asco24.
Learn more about our upcoming presentation: meetings.asco.org/abstracts-presentations/233875 -
Molecular Partners
@MolecularPrtnrs
On this day last month, we kicked off a great #swissbiotechday, where we connected with biotech leaders, investors & future partners. Highlights were several panel discussions & presentations on Life Science Cares Switzerland, investors, #radioligand therapies & MP’s progress.
-
Molecular Partners
@MolecularPrtnrs
Today we announced our Q1 results. Learn more about our 2024 progress & plans: investors.molecularpartners.com/news-releases/news-releas…
We also announced three upcoming presentations. Join us at #asco, #snmmi and #eha2024 in June.
$MOLN -
Molecular Partners
@MolecularPrtnrs
The beautiful spring weather gives us many great opportunities to get active & connect with each other outside of the office. Last week at the 49th #asvz #sola relay, our team ran 115 km across Zürich.
Congrats to all runners and teams that participated! -
Molecular Partners
@MolecularPrtnrs
We’re looking forward to updating on #switchdarpin & #rdt at #pegsummit. Stop by SVP Research & Tech Daniel Steiner’s presentation as he unveils the future of protein therapeutics, delving into the design, mechanisms & therapeutic potential of next-generation DARPin-based drugs.
-
Molecular Partners
@MolecularPrtnrs
We’re proud of our #oncology pipeline, including our #radiodarpin Therapy platform. The high affinity and specificity of DARPins to selectively target tumors allow us to expand the proven potential of #radioligand therapies.
#ncrm24 -
Molecular Partners
@MolecularPrtnrs
New Publication: We and our partner @Novartis published Phase 2 clinical data on ensovibep, our #darpin candidate for COVID-19. While clinical work on the ensovibep program ended in 2022, it provided important clinical validation of DARPins in #virology.
academic.oup.com/ofid/advance-article/doi/10.1093/ofid/of… -
Molecular Partners
@MolecularPrtnrs
May is #nationalcancerresearchmonth. By harnessing the unique advantages of #darpins, we are developing novel treatments for people with cancer, including MP0533, a novel tetra-specific #darpin therapy in clinical development for patients with AML.
#ncrm24 -
Molecular Partners
@MolecularPrtnrs
Last week, we had the pleasure of hosting students from the Biochemistry Student Association of Zürich (@ETH_en) at our headquarters to network and provide helpful insights into managing uni years and enjoying life in and outside the lab.
More: www.biocz.ch/molecularpartners2024 -
Molecular Partners
@MolecularPrtnrs
Today we announced the publication of comprehensive preclinical data in Cancer Immunology Research @CIR_AACR that support MP0533’s mechanism of action for patients with relapsed/refractory AML and AML/MDS.
Learn more in the full paper here: aacrjournals.org/cancerimmunolres/article/doi/10.1158/232… -
Molecular Partners
@MolecularPrtnrs
Today at #immuno2024, MP Sr. Scientist Natalia Venetz will present on #darpins as a novel therapeutic modality, discussing conditionally activated DARPin therapeutics for #immunooncology, MP0533 and Switch-DARPin.
More: oxfordglobal.com/nextgen-biomed/
@OGConferences -
Molecular Partners
@MolecularPrtnrs
Today at #swissbiotechday, our SVP Research & Tech Daniel Steiner will join #radiopharma experts in an exciting discussion on our RDT platform & how #swiss companies are leading this next era of innovation for cancer patients.
Details: swissbiotechday.ch/panel_discussion_2024/molecular-partne… -
Molecular Partners
@MolecularPrtnrs
Today at #swissbiotechday, join @SwissBiotech President & MP CEO Patrick Amstutz and EVP People & Community Renate Gloggner as they introduce Life Science Cares Switzerland, an org uniting Swiss life science community with local communities and charitable organizations.
-
Molecular Partners
@MolecularPrtnrs
At #swissbiotechday, join @SwissBiotech President & MP CEO Patrick Amstutz as he premieres Life Science Cares; our SVP IR for an investors panel; our SVP Research & Tech for an MP-sponsored radioligand therapy panel; & our COO for a company presentation.
-
Molecular Partners
@MolecularPrtnrs
Next week on Wednesday, April 17, MP will be hosting our Annual General Meeting at 9am CET.
Preview the full agenda here and join us in a discussion of key business issues: investors.molecularpartners.com/events/event-details/annu…
$MOLN -
Molecular Partners
@MolecularPrtnrs
MP is proud to offer generous benefits to its employees to foster a healthy work environment. These flexible working arrangements allow our team to care for their families, incentivize public transportation and cycling to work, and make time for their interests outside of work.
-
Molecular Partners
@MolecularPrtnrs
Last week our MP colleagues gathered for our Spring Social to debrief the Spring Portfolio Review and celebrate our hard work to expand #darpins’ potential to help patients through innovative approaches.
#swissbiotech #oncology #darpin #radiodarpins -
Molecular Partners
@MolecularPrtnrs
In his role as the chairman of @SwissBiotech, our CEO Patrick Amstutz will be presenting at the upcoming #swissbiotechday2024. We look forward to the opportunity to continue to build bridges with other leading life science clusters around the world.
More: swissbiotechday.ch -
Molecular Partners
@MolecularPrtnrs
Spring is in the air! Our teammates in Zürich are excited to take advantage of the soon-to-come warmer weather through initiatives like the bike-to-work challenge & tending to our community garden, kept by our employee-run group of plant & bee lovers, the wonderful balcony team.
-
Molecular Partners
@MolecularPrtnrs
Recently, CEO Patrick Amstutz & SVP of Research & Early Dev Anne Goubier caught up with Boston-based colleagues at the @TDCowen Health Care Conference to share the latest developments of our portfolio. Shooting hoops at the @TDGarden was a great way to connect at the conference!
-
Molecular Partners
@MolecularPrtnrs
Today we announced our corporate highlights and financial results for 2023, which we will be discussing on a conference call tomorrow, March 15, at 1:00pm CET/8:00am ET.
For more details, see our press release: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
This #iwd2024, we’re celebrating the achievements of the women on our team who are working to deliver novel #darpin therapeutics to patients.
We recently hosted a Lunch & Learn to share our commitment to #genderequality at MP and uplifting #womeninstem. www.unwomen.org/en/news-stories/announcement/2023/12/inte… -
Molecular Partners
@MolecularPrtnrs
MP will share both our fourth quarter and full year 2023 financial results on March 14. We’re also looking forward to presenting at the #tdcowen 44th Annual Health Care Conference and attending the Leerink Global Biopharma Conference this month.
Details: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
MP0317 is our CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to FAP. This MoA aims to activate immunity directly in the tumor with fewer systemic side effects.
-
Molecular Partners
@MolecularPrtnrs
On #worldcancerday, we’re advocating for innovative treatments for patients.
We have several #oncology programs and platforms in our pipeline, including MP0533, MP0317, RDT and Switch-DARPin. Hear from our colleague Suzana Peras on what motivates her to work on MP0533! -
Molecular Partners
@MolecularPrtnrs
We recently announced our partnership with @OranoMed to co-develop Radio-DARPin Therapies (RDTs) for solid tumors.
MP’s RDT platform enables us to selectively target tumors through #darpins’ high affinity & specificity to expand the proven potential of #radioligand therapies. -
Molecular Partners
@MolecularPrtnrs
January has been an exciting month for us, as CEO Patrick Amstutz, COO Alexander Zürcher and other members of our team attended #jpm24 and the Baader Helvea Swiss Equities Conference. We look forward to sharing our progress in the year ahead!
-
Molecular Partners
@MolecularPrtnrs
Today we’re excited to introduce our Switch-DARPin platform for targeted and conditional immune activation as well as to present our other progress at #jpm24.
Learn more about how our Switch-DARPin platform works below or on our website: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
This week at #jpm24, our CEO Patrick Amstutz will present on exciting updates from our MP0533 program, Radio-DARPin Therapy pipeline, Switch-DARPin platform & upcoming milestones in 2024.
We hope to see you at 10:30 am PT for his presentation!
More: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Today we announced a co-development agreement with @OranoMed.
We’ll advance lead-212 based Radio-DARPin Therapies (RDT) for solid tumors, building on our existing RDT programs & partnership.
We'll discuss this & other exciting developments at #jpm24.
investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
NEW #jpm24 TIMESLOT: Our CEO Patrick Amstutz will be presenting on Wednesday, Jan 10th at 10:30 am PT (1:30 pm ET/7:30 pm CET).
More: investors.molecularpartners.com/events/event-details/42nd…
#darpins #radiodarpins #radiopharma #oncology #hematology #bloodcancer #acutemyeloidleukemia #cancer #immunooncology -
Molecular Partners
@MolecularPrtnrs
On behalf of the team at Molecular Partners, we wish everyone a happy and healthy holiday season!
-
Molecular Partners
@MolecularPrtnrs
As the year ends, we’re reflecting on the progress we’ve made.
From important clinical & DARPin platform advancements to spending time with each other, 2023 was marked by a commitment to expanding #darpin capabilities for the benefit of patients.
We look forward to 2024! -
Molecular Partners
@MolecularPrtnrs
We’re looking forward to #jpm24, where our CEO Patrick Amstutz will be presenting. MP leadership will also be at the #baaderhelvea Swiss Equities Conference & the Octavian Seminar for presentations & meetings with the Swiss investment community. investors.molecularpartners.com/news-releases/news-releas…
#darpins -
Molecular Partners
@MolecularPrtnrs
We’re excited to be going to San Francisco next month to attend the J.P. Morgan Healthcare Conference! We look forward to sharing more about our recent progress, upcoming plans and connect with both old friends and new faces at the conference. #jpm24
investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
We had a great time presenting initial positive results from MP0533 at #ash23 this year and connecting with so many dedicated researchers who are as committed as we are to transforming the lives of patients.
#cancer
#bloodcancer
#aml
#hematology
#immunooncology
#darpins -
Molecular Partners
@MolecularPrtnrs
Today we presented positive initial data from the first four dosing cohorts of our ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at #ash23. Learn more in our full announcement: shorturl.at/qt458
Molecular Partners
@MolecularPrtnrs
-
Molecular Partners
@MolecularPrtnrs
We will be attending #ash23 to share initial results from our Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML & AML/MDS. Join us at our poster on Dec 10 at 6 – 8PM PT, which will be made available on our website after the presentation. investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Our SVP of Research, Daniel Steiner, recently presented our DARPin engineering capabilities at #pegseurope.
Our SWITCH-DARPin platform is just another example of how we leverage our DARPin platform & capabilities for conditional activation to continue to innovate for patients. -
Molecular Partners
@MolecularPrtnrs
Earlier this month for #zukunftstag, we welcomed students to our HQ to inspire them and trigger their curiosity with fun lab experiments. We had a wonderful time sharing our passion for science, and doing so in partnership with @Roche and @CaritasSwiss.
#nationalfutureday -
Molecular Partners
@MolecularPrtnrs
MP is hiring! We have openings at a variety of levels on our lead generation & preclinical teams. We’re looking for driven individuals to join us in developing breakthrough medicines for patients with serious diseases. Learn more: www.molecularpartners.com/careers/
-
Molecular Partners
@MolecularPrtnrs
Today at #pegseurope, our SVP of Research, Daniel Steiner, Ph.D., will give a presentation about how we’re leveraging conditional activation of #darpins to create different, novel mechanisms of action.
Learn more: investors.molecularpartners.com/news-releases/news-releas…
#immunooncology #cancer -
Molecular Partners
@MolecularPrtnrs
We are excited to attend @UBS Swiss Equity Technology and Innovation Days and @Jefferies London Healthcare Conference this week to discuss our latest progress and opportunities for further innovation.
#darpins
#radiodarpins
#immunooncology
#cancer
#radioligands
#radiopharma -
Molecular Partners
@MolecularPrtnrs
Today is #nationalfutureday in Switzerland. This year, we are proud to join forces with @Roche and @CaritasSwiss to enable children with little exposure to the biotechnology industry to spend the day with us at our office in Zürich.
#nationalerzukunftstag #zukunftstag -
Molecular Partners
@MolecularPrtnrs
This week, we are attending #bioeurope in Munich to meet with potential partners to build on synergies, leverage capabilities and create new opportunities for our #darpin platform.
We look forward to sharing the latest progress across our #oncology programs! -
Molecular Partners
@MolecularPrtnrs
Our team will be sharing updated positive data from our ongoing Phase 1 trial of MP0317, our #darpin candidate that targets CD40 & fibroblast activation protein, in patients with advanced solid tumors at the 2023 @sitcancer Annual Meeting today.
investors.molecularpartners.com/news-releases/news-releas…
#sitc23 -
Molecular Partners
@MolecularPrtnrs
We will be sharing the initial results from our ongoing Phase 1/2a trial of MP0533 for the treatment of relapsed/refractory AML and MDS at the @ASH_hematology Annual Meeting next month.
Learn more: investors.molecularpartners.com/news-releases/news-releas…
#ash23
#darpins
#cancer
#immunooncology -
Molecular Partners
@MolecularPrtnrs
Later this week, we will be attending @TDCowen’s 7th Annual Fall Oncology Innovation Summit.
Read our press release for more details: investors.molecularpartners.com/news-releases/news-releas…
We look forward to seeing you there!
#sitc23 -
Molecular Partners
@MolecularPrtnrs
We will present updated clinical results on MP0317 from our Phase 1 trial in patients with advanced solid tumors at @sitcancer’s 2023 Annual Meeting this week. We look forward to meeting you at our poster on Friday, Nov 3rd!
Watch our video below to learn about MP0317.
#sitc23This media couldn't be displayed. See it on the original post. -
Molecular Partners
@MolecularPrtnrs
Today we announced our corporate highlights & unaudited financial results for Q3 2023. We also announced our plans to present data from MP0317 at #sitc23 & MP0533 at #ash23.
More on our plans & progress towards our goal of helping patients: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
One of the things that makes working here special is that our team is dedicated to developing a new class of drugs. We recently gathered to celebrate employees who have been with the company over 10 years and whose hard work has helped us pioneer our #darpin platform.
#darpins -
Molecular Partners
@MolecularPrtnrs
We pioneered the class of #darpin therapeutics to uncover opportunities to treat patients with serious diseases. Building on DARPins’ innate characteristics & our expertise, we’re working to expand versatility & potential of these proteins for patients: www.molecularpartners.com/darpin-biology/
-
Molecular Partners
@MolecularPrtnrs
We are called Molecular Partners for a reason. Our team believes that strong external collaborations are important to realize the full potential of #darpin therapeutics for patients.
To learn more about partnering with us, please visit: www.molecularpartners.com/partnering/
#radiodarpins -
Molecular Partners
@MolecularPrtnrs
Recently, MP co-founder Michael Stumpp, Ph.D. participated in a @SAKK_ch Industry Pool to share how we hope to transform the lives of cancer patients through #darpin therapeutics. On #worldcancerresearchday, we are proud to be part of #oncology industry discussions like this!
-
Molecular Partners
@MolecularPrtnrs
September is #bloodcancerawarenessmonth. Each year, about 190,000 people worldwide are diagnosed with #acutemyeloidleukemia (AML), a highly resistant type of #bloodcancer.
Learn about our MP0533 candidate, designed to treat AML: www.molecularpartners.com/pipeline/
#fightbloodcancer
#darpin -
Molecular Partners
@MolecularPrtnrs
We are pleased to announce new preclinical data on our Radio DARPin Therapy (RDT) Platform, which we presented today at the @EANM_NucMed 2023 Annual Meeting. Details: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
We’re sharing an exciting new dimension for our Radio DARPin Therapy (RDT) Platform at the @EANM_NucMed 2023 Congress in Vienna, Austria. We look forward to meeting you at our presentation on Wednesday, September 13th!
#eanm23
#darpin -
Molecular Partners
@MolecularPrtnrs
Join our team! We are seeking a Technical Project Lead – Lead Generation to join our team in Zürich.
If you share our passion for innovation, click here to learn more: www.molecularpartners.com/careers/
#biotechjobs
#cancerresearch
#darpin -
Molecular Partners
@MolecularPrtnrs
We are excited to announce our corporate highlights and financial results for the first half of 2023 today: investors.molecularpartners.com/news-releases/news-releas… $MOLN
-
Molecular Partners
@MolecularPrtnrs
#meettheteam: Dr. Philippe Legenne is our VP of Clinical Development & External Scientific Relations.
He leads both our clinical development &
operations teams, as well as scientific engagements to generate a rich flow of external expert insights to Molecular Partners. #darpin -
Molecular Partners
@MolecularPrtnrs
Our team has continually expanded our technical capabilities and further unlocked the potential of our #darpin platform by creating new solutions for defined clinical challenges.
Learn more about the unique advantages of #darpins: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
Today we wish our entire team, @SwissBiotech group, families, and friends a very happy #swissnationalday!
#swissbiotech -
Molecular Partners
@MolecularPrtnrs
#meettheteam Michael Stumpp, Ph.D. is our EVP Projects & a Member of the Management Board.
As a co-founder of the company & one of the inventors of #darpin technology, Dr. Stumpp has been a key piece of our history.
Learn more about our leadership team: www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
#darpins can block multiple targets at once, making it harder for a virus or cancer cell to break through with single mutations. This is postulated to increase efficacy of our candidates, e.g. #mp0317, #mp0533, even against evolving targets.
-
Molecular Partners
@MolecularPrtnrs
The delicious grill food, refreshing drinks, and the amazing #teamspirit made our recent Swiss #corporatesummerevent a highlight of the year! We proudly carry the same enthusiasm into our work to pioneer #darpin therapeutics to go beyond the limits of today’s leading treatments.
-
Molecular Partners
@MolecularPrtnrs
We have enjoyed taking part in #biketowork for the past two months! Thank you to our Molecular Partners team and to all who participated. We look forward to continuing our biking throughout the rest of the year! #biketoworkmoments
-
Molecular Partners
@MolecularPrtnrs
#icymi: Director of Partnering & Alliances Christian Lizak, Ph.D. recently attended @SNM_MI’s Annual Meeting to present on our Radio #darpin Therapy Platform. It was great to connect and discuss the latest with other industry experts!
Learn more: investors.molecularpartners.com/static-files/8fcd61a3-38f…
#snmmi -
Molecular Partners
@MolecularPrtnrs
Wishing our team and everyone in the United States a very happy Independence Day!
-
Molecular Partners
@MolecularPrtnrs
#mp0533 is our first DARPin T-cell engager candidate. It’s being developed as a unique multi-specific treatment for #aml. MP0533 is designed to deliver a deeper attack on a broader range of tumor cells, while lowering the risk to healthy cells.
Learn more: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
We are looking forward to sharing an update on our Radio #darpin Therapy Platform at @SNM_MI’s Annual Meeting next week. It is a great opportunity to listen to Christian Lizak, PhD, & learn more about the development of powerful targeting agents for #rdt. web.cvent.com/event/0ec6d892-f2be-4e22-bf09-906a7e556cf8/…
-
Molecular Partners
@MolecularPrtnrs
Molecular Partners is proud to be part of the research making #cancerimmunotherapymonth possible. We are continually pushing the boundaries of #darpins for patients worldwide.
Learn more:
www.molecularpartners.com/darpin-biology/
#mp0533 #mp0317 -
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz and SVP of Research Daniel Steiner will be presenting a fireside chat at the @TDCowen Radiopharmaceutical Innovation Summit today from 12:00 – 12:25 PM ET. Learn more in our press release: investors.molecularpartners.com/news-releases/news-releas… $MOLN
-
Molecular Partners
@MolecularPrtnrs
#meettheteam Marianne Jenal-Eyholzer, PhD, CMPP™ is our new Director of Scientific Communications!
Marianne has more than a decade of experience in the global pharma setting with expertise in pharmaceutical sciences, hematology/oncology, and rare diseases. -
Molecular Partners
@MolecularPrtnrs
Happy #pridemonth from Molecular Partners! We are proud to support the LGBTQIA+ community inside and outside our team and are committed to promoting a safe and inclusive environment for all. #pride2023
-
Molecular Partners
@MolecularPrtnrs
As a team that researches and develops #cancer treatments, it was poignant being at @ASCO on #nationalcancersurvivorsday. We reflected on the powerful stories of #cancersurvivors and the essential work that remains to push the frontiers of #cancerresearch.
#asco23 -
Molecular Partners
@MolecularPrtnrs
Today is #worldbicycleday and for the past month, Molecular Partners has been taking part in the #biketowork challenge. We are excited to continue the challenge through the end of June #biketoworkmoments
-
Molecular Partners
@MolecularPrtnrs
Tomorrow we will present at @ASCO on the latest clinical data from #mp0317, our #darpin candidate designed to activate immune cells specifically in tumors – not the rest of the body.
#asco23 #cd40 #fibroblastactivationprotein -
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz will be attending the @IAmBiotech Convention in Boston to connect with global biotech leaders and share the promise of #darpins.
#bio2023 -
Molecular Partners
@MolecularPrtnrs
We are looking forward to @ASCO’s General Meeting where we will be presenting the latest updates on the Phase I study of #mp0317, our #darpin program designed to activate immune cells specifically in tumors investors.molecularpartners.com/news-releases/news-releas…
#asco23 #cd40 #fibroblastactivationprotein -
Molecular Partners
@MolecularPrtnrs
Tomorrow is #clinicaltrialsday, and we want to thank our team members, partners, and patients who participate in #clinicaltrials so innovative medicines can reach more people in need.
Learn more: www.molecularpartners.com/pipeline/
#ictd23 #cancerresearch #darpins #mp0317 #mp0533 #aml -
Molecular Partners
@MolecularPrtnrs
Alex Zürcher is our COO and Member of our Management Board. Alex has more than 20 years of industry experience and prior work in drug development.
Learn more about Alex and our leadership: www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
During May and June, Molecular Partners is participating in the Bike to Work Challenge, Switzerland’s largest cycling campaign with over 80,000 people.
Keep an eye out here for updates from our team! Learn more about the program here: www.biketowork.ch
#biketoworkmoments -
Molecular Partners
@MolecularPrtnrs
Today we released our first quarter results. Learn more about our 2023 progress and our upcoming plans: investors.molecularpartners.com/news-releases/news-releas… $MOLN
-
Molecular Partners
@MolecularPrtnrs
We were proud to have a team represent #molecularpartners in the #asvz #sola relay this past weekend!
Our team ran nearly 115km in the Zurich area. Congratulations to our runners!
Molecular Partners
@MolecularPrtnrs
Check out this video of some of Team #darpinrunners!
-
Molecular Partners
@MolecularPrtnrs
Our #mp0533 is designed to overcome many of the existing challenges of acute myeloid leukemia treatment by binding to CD3 on T cells and either two or three tumor-associated antigens to selectively kill AML cells, while sparing healthy cells
Learn more: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Yesterday marked the start of #nationalcancerresearchmonth. We’re working to develop novel treatments for cancer by harnessing #darpins unique advantages. Our #mp0317 therapeutic candidate is the perfect example of that. Learn more about how #mp0317 works in this video:
#ncrm23This media couldn't be displayed. See it on the original post. -
Molecular Partners
@MolecularPrtnrs
This year at #swissbiotechday, @SwissBiotech celebrated 25 years since its founding!
Our CEO Patrick Amstutz has chaired the SBA since last year, inspiring others with his entrepreneurial experience.
Congratulations SBA! The best is yet to come!
#swissbiotech -
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz was thrilled to meet so many international delegations at #swissbiotechday!
Thank you to the representatives of @TIQld_Europe @BusinessOregon @invest_canada India, Taiwan, and more for building international bridges with us
#swissbiotech #biotechindustry -
Molecular Partners
@MolecularPrtnrs
As part of #swissbiotechday, Molecular Partners was proud to support George Scangos’s presentation of @LS_Cares and highlight the addition of the first chapter outside the U.S. in Switzerland in the near future!
Learn more about their work here: lifesciencecares.org -
Molecular Partners
@MolecularPrtnrs
Thank you to everyone who joined us for our company overview presentation at #swissbiotechday this week led by our COO Alexander Zürcher. We had a full house!
If you’re interested in learning more about DARPins’ advantages, be sure to visit our website: www.molecularpartners.com -
Molecular Partners
@MolecularPrtnrs
At #swissbiotechday we're connecting with our peers and sharing more about our science. Here's to another great year of innovation for #swissbiotech!
-
Molecular Partners
@MolecularPrtnrs
Today we kick off #swissbiotechday 2023!
Our CEO and President of the @SwissBiotech Patrick Amstutz will deliver opening remarks in Room Montreal at 13:10 CET. At 15:45 CET in Room Rio our COO Alexander Zürcher will present a company overview.
We hope you'll join us!
Molecular Partners
@MolecularPrtnrs
We are looking forward to #swissbiotechday 2023, which is shaping up to be the largest event to date!
As the President of the @SwissBiotech, our CEO Patrick Amstutz will provide several updates throughout the event. COO Alexander Zürcher will present a company overview as well. -
Molecular Partners
@MolecularPrtnrs
We are looking forward to #swissbiotechday 2023, which is shaping up to be the largest event to date!
As the President of the @SwissBiotech, our CEO Patrick Amstutz will provide several updates throughout the event. COO Alexander Zürcher will present a company overview as well. -
Molecular Partners
@MolecularPrtnrs
We’ve continually unlocked DARPins’ advantages over other approaches by combining our deep expertise with leading collaborators.
Learn more about our partnerships and how you can collaborate with us: www.molecularpartners.com/partnering/ -
Molecular Partners
@MolecularPrtnrs
Our team will be sharing updates on our Radio DARPin Therapy platform at @AACR today, including its continued potential to reduce radiotherapy accumulation in the kidneys and DARPins’ potential to offer high tumor penetration.
Read more: investors.molecularpartners.com/news-releases/news-releas…
#aacr23 -
Molecular Partners
@MolecularPrtnrs
We are looking forward to @AACR’s Annual Meeting where our team will present a poster on the progress of our Radio DARPin Therapy platform.
Learn more: investors.molecularpartners.com/news-releases/news-releas…
#aacr23 -
Molecular Partners
@MolecularPrtnrs
We come to work inspired to advance DARPins as a new class of drugs because we know the potential of our platform to overcome the challenges of other therapies.
This #worldhealthday, we’re reflecting on the possibilities to transform the lives of patients with our science. -
Molecular Partners
@MolecularPrtnrs
It was a pleasure to meet our shareholders at our Annual General Meeting to provide an overview of our pipeline and financial year 2022. All motions proposed by the Board of Directors were approved by a wide majority. Learn more here: investors.molecularpartners.com/news-releases/news-releas…
$MOLN -
Molecular Partners
@MolecularPrtnrs
Next week on Tuesday April 4th we will be hosting our Annual General Meeting at 2 pm CET (8 am ET). Learn more about the agenda: investors.molecularpartners.com/general-meeting
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, we leverage the many intrinsic advantages of #darpins therapeutics.
Every dose received contains more molecules per gram than a larger molecule like an antibody, which provides a range of advantages including better tumor penetration. -
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, we leverage the many intrinsic advantages of #darpins therapeutics.
Every dose received contains more molecules per gram than a larger molecule like an antibody, which provides a range of advantages including better tumor penetration. -
Molecular Partners
@MolecularPrtnrs
Vice President of Partnering & Alliances Julia Hepp and Director Partnering & Alliances Christian Lizak presented on our Global Partnerships work at @EBDGroups’s Bio-Europe Spring this week. Learn more about our partnerships: www.molecularpartners.com/partnering/
#bioeuropespring -
Molecular Partners
@MolecularPrtnrs
Earlier this month our CEO Patrick Amstutz and SVP of Biology Anne Goubier were in Boston for the @tdcowen conference and to catch up with our U.S. team, who didn't disappoint. Shooting hoops at the @tdgarden with our SVP of IR Seth Lewis was a great way to end the week!
-
Molecular Partners
@MolecularPrtnrs
Spring has officially sprung, and our terrace greenery is just around the corner!
In honor of spring equinox, here is a glimpse from our garden in Zürich created by our employees. This tranquil space offers our teammates the perfect spot soak in the fresh air.
#swissbiotech -
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, we are developing an entirely new class of biologic medicines.
What’s our goal?
To transform the lives of people with cancer and other serious diseases through #darpin therapeutics.
Learn more about how to join us: www.molecularpartners.com/careers/
#biotechjobs -
Molecular Partners
@MolecularPrtnrs
MP0553 is our novel tri-specific T cell engager to treat AML which engages CD3 on T cells while binding to three tumor-associated antigens with increasing strength. This ‘avidity-driven’ binding activates T cells and results in immune attack on AML cells.
#darpins -
Molecular Partners
@MolecularPrtnrs
Today we announced our corporate highlights and financial results for 2022.
For more details on our progress, see our latest press release: investors.molecularpartners.com/news-releases/news-releas…
$MOLN -
Molecular Partners
@MolecularPrtnrs
Happy International @womensday! We proudly continue to celebrate the achievements of the women on our team working to deliver #darpins as a new class of medicines.
For more on how we all can collectively #embraceequity every day, visit: www.internationalwomensday.com
#iwd2023 -
Molecular Partners
@MolecularPrtnrs
We are looking forward to @TDCowen’s 43rd Annual Health Care Conference this morning, where our CEO, Patrick Amstutz, will provide a company overview at 9:10am ET.
For more on our recent updates, visit: investors.molecularpartners.com/news-and-events/news-rele… -
Molecular Partners
@MolecularPrtnrs
Today is #employeeappreciationday and we are grateful for our pioneering teammates at Molecular Partners.
Thank you for your focus, innovation and dedication towards moving beyond boundaries to transform the lives of patients through our new class of #darpin therapeutics. -
Molecular Partners
@MolecularPrtnrs
Molecular Partners will share both fourth quarter and full year financial results next week. We’re also looking forward to attending the @TDCowen Health Care Conference, where our CEO, Patrick Amstutz, will share a company overview.
For more: investors.molecularpartners.com/news-releases/news-releas…
#tdcowen -
Molecular Partners
@MolecularPrtnrs
#meettheteam – We are thrilled to recently welcome Antonio Ligi, Head of Communications! Antonio brings previous international communications experience at top global newsrooms and pharmaceutical companies including @Novartis.
Learn more about our team: www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
Today our SVP of Research, Daniel Steiner, Ph.D., will present at the 12th International Symposium on Targeted Alpha Therapy (TAT 12) hosted by @UPTuks. Dr. Steiner will discuss our #darpin radioligand therapy platform progression.
Click here for more: tat-12.com/about-the-congress/ -
Molecular Partners
@MolecularPrtnrs
We recently shared that we’ve officially selected the tumor-associated protein Delta-like ligand 3 (DLL3) as the target candidate for our #darpin radioligand therapy.
To explore the rest of our pipeline, visit: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
We are searching for individuals ready to contribute to our mission to deliver #darpins as a new class of medicines to patients across the globe.
Learn more about our collaborative and passionate working environment: www.molecularpartners.com/careers/
#biotechjobs -
Molecular Partners
@MolecularPrtnrs
Tomorrow our SVP of Biology, Anne Goubier, D.V.M., Ph.D, will present on MP0533, our trispecific T cell engager #darpin candidate at the European Bispecific & Multispecific Antibody Congress hosted by @KisacoRes.
For more on Dr. Goubier and our research: kisacoresearch.com/sites/default/files/documents/ann_goub… -
Molecular Partners
@MolecularPrtnrs
Our CMO Dr. Nicolas Leupin spoke to aspiring scientists about opportunities beyond academia at @LSZYSN’s Day.
“Yes, you can, if you really want it. Molecular Partners began as a @UZH_en spin-off & became a NASDAQ-listed company with its proprietary DARPin technology.”
#zlsd23 -
Molecular Partners
@MolecularPrtnrs
Our team has grown to 180+ exceptional individuals who share a collective vision of scientific excellence and teamwork. We are proud to remain committed to the professional growth and achievements of our team!
For more: www.molecularpartners.com/about-us/
#biotechjobs -
Molecular Partners
@MolecularPrtnrs
#meettheteam and get to know one of our Senior Scientists, Dr. Julia Ahlskog!
Dr. Ahlskog earned a Ph.D. in antibody engineering from ETH Zurich and is a leader for #darpin generation and design in immune oncology.
Learn more about our team:
www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
We’re looking forward to our fireside chat, hosted by biotechnology analyst Daina Graybosch, at the 2023 @SVB_Financial Securities Global Biopharma Conference this week.
To tune in to this webcast and learn more about recent company updates, visit: investors.molecularpartners.com/events/event-details/svb-… -
Molecular Partners
@MolecularPrtnrs
We’re celebrating International @WomenScienceDay!
Today we will feature multiple #womeninscience from our team to share what #science means to them as leaders in their field.
Join us in celebration and learn more about #february11 here: www.womeninscienceday.org.
#idwgis #stemPost not available here, view on X
Molecular Partners
@MolecularPrtnrs
“Science allows us to create exciting predictions and innovations like our #darpin molecules that aim to treat serious diseases. As leader in this industry, I can foster a diverse community and support gender balance to embrace progress.”- Lotti Frauchiger Ravatn, Ph.D.
Molecular Partners
@MolecularPrtnrs
“Being part of a highly skilled, driven team that works together to develop therapeutics and improve patients’ lives brings energy to my work. I see science as an endless opportunity to learn and better understand the world.” - Clara Domke
#idwgis #womeninscience #february11 -
Molecular Partners
@MolecularPrtnrs
We’re leveraging DARPins’ unique advantages and our experience from developing six clinical-stage programs to continually deliver new solutions for complex diseases.
Learn more about our #darpin therapeutics platform: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
While today is #worldcancerday, our team is on a mission every day to transform the lives of people with #cancer through #darpin therapeutics.
Learn more about MP0317, MP0533, and our other #oncology programs in development: www.molecularpartners.com/pipeline/
#cancerresearch -
Molecular Partners
@MolecularPrtnrs
Last week, our CEO Patrick Amstutz hosted @SwissBiotech Annual CEO Meeting at @sixgroup.
“Let us continue the great work, be proactive and positive, and keep a relentless focus on our purpose to deliver value for patients and drive innovation.”
#swissbiotech -
Molecular Partners
@MolecularPrtnrs
Yesterday we announced that the first patient has been dosed in our study of MP0533, our trispecific candidate for AML with a novel mechanism that is designed to selectively target cancerous cells, while sparing healthy ones: investors.molecularpartners.com/news-releases/news-releas…
#cancerresearch -
Molecular Partners
@MolecularPrtnrs
Ready to advance your career in the new year?
Join our growing team that shares a passion to provide better treatment options for patients with serious diseases.
Check out our open positions and learn more about our team: www.molecularpartners.com/careers/
#biotechjobs -
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, we proudly offer flexible work arrangements.
A #hybridworkplace gives our team members the opportunity to maintain #worklifebalance as we continue pioneering a new class of biological medicines.
Learn more: www.molecularpartners.com/careers/ -
Molecular Partners
@MolecularPrtnrs
Today is the first day of the 41st Annual @jpmorgan Health Care Conference! Our CEO Patrick Amstutz will be presenting a company overview on Wednesday, January 11th at 7:30a.m. PT.
Read more in our latest press release: investors.molecularpartners.com/news-releases/news-releas…
#jpm2023 -
Molecular Partners
@MolecularPrtnrs
Today we announced a number of developments in our infectious disease and immuno-oncology portfolios. Read the full announcement here: investors.molecularpartners.com/news-releases/news-releas…
More will also be shared in our presentation at the @jpmorgan Health Care Conference this week so stay tuned!
#jpm2023 -
Molecular Partners
@MolecularPrtnrs
Our team has continually expanded the possibilities of our #darpin platform by creating solutions for defined clinical challenges.
Next week at the @jpmorgan Health Care Conference, we will share more on our rapid clinical progress and next-generation capabilities.
#jpm2023 -
Molecular Partners
@MolecularPrtnrs
We are looking forward to heading to San Francisco next week for the 41st Annual @jpmorgan Health Care Conference! Our CEO Patrick Amstutz will be in attendance and is presenting a company overview.
#jpm2023 -
Molecular Partners
@MolecularPrtnrs
We are wishing our outstanding team, partners, patients, and providers a very happy holiday season!
-
Molecular Partners
@MolecularPrtnrs
This was a year full innovation and progress. We are proud of the steps we took towards delivering #darpins as a new class of medicines for patients living with complex diseases around the world.
We look forward to all that 2023 will bring! -
Molecular Partners
@MolecularPrtnrs
We’re proud to be recognized by Great Place to Work Switzerland’s annual survey as one of the best workplaces in the country! Learn more about why we were selected: greatplacetowork.ch/arbeitgeber/molecular-partners-ag/
Head to our website to learn how you can join our growing team: www.molecularpartners.com/careers/ -
Molecular Partners
@MolecularPrtnrs
#meettheteam – Last month we welcomed Michael Pitzner to Molecular Partners as General Counsel & Compliance Officer, Senior Vice President Legal. Michael joins us with over two decades of experience providing external and internal counsel at numerous biotech and pharma companies.
-
Molecular Partners
@MolecularPrtnrs
Our team had a wonderful time in New Orleans at @ASH_hematology’s Annual Meeting!
Thank you to all who joined our MP0533 oral presentation and reception.
#bloodcancer #hematology #ash22 -
Molecular Partners
@MolecularPrtnrs
We value the unique needs of each team member at Molecular Partners. Our health, wellness, and retirement planning benefits ensure that everyone can perform their best work while maintaining a healthy #worklifebalance.
Learn more: investors.molecularpartners.com/environmental-social-and-… -
Molecular Partners
@MolecularPrtnrs
Today at @ASH_hematology’s Annual Meeting we will present positive data about our multi-specific #darpin CD3 engager, MP0533. Our Phase 1 of MP0533 study is on track to be initiated by year-end.
Read more: investors.molecularpartners.com/news-releases/news-releas…
#ash22 -
Molecular Partners
@MolecularPrtnrs
We look forward to hosting a reception at @ASH_hematology this upcoming Saturday night, December 10th at 7:30pm CST, to discuss our tetra-specific MP0533 #darpin candidate for AML.
Learn more about how to join us: investors.molecularpartners.com/events/event-details/mole…
#hematology #bloodcancer #ash22 -
Molecular Partners
@MolecularPrtnrs
Our team is growing!
Come join our curious, innovative and passionate team as we work collaboratively to advance new treatment options for patients with serious diseases.
Learn more about our openings and company culture: www.molecularpartners.com/careers/
#biotechjobs #darpins -
Molecular Partners
@MolecularPrtnrs
Last week, we were proud to celebrate our 18th birthday! Our team’s vision to pioneer #darpins as a new class of drugs has made significant progress over the last year and we look forward to continuing that momentum as we advance multiple programs through clinical trials in 2023.
-
Molecular Partners
@MolecularPrtnrs
#icymi, this month we presented positive clinical data from our MP0317 program at @sitcancer’s Annual Meeting. MP0317 is our #immunooncology candidate designed to locally activate immune cells through the binding of CD40 & FAP. Learn more: www.molecularpartners.com/pipeline/
#cancerresearch -
Molecular Partners
@MolecularPrtnrs
Dr. Nicolas Leupin, medical oncologist, CMO, and Member of the Management Board, oversees the clinical development of our #darpin candidates.
Next month he’ll be attending #ash22 to share more about MP0533, our tetra-specific AML candidate set to enter the clinic this year. -
Molecular Partners
@MolecularPrtnrs
Our team is as committed to making a positive impact for patients as they are for our planet.
Now in its seventh year, our bike-to-work program is a sign of how the small steps we take every day adds up to large gains over time.
Learn more: investors.molecularpartners.com/environmental-social-and-… -
Molecular Partners
@MolecularPrtnrs
#dyk that #darpins have the potential to initiate local #immune activation with reduced risk of systemic inflammation?
DARPins candidates can be designed to bind to proteins that cluster on the surface of tumors to initiate a local response.
Learn more: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
We look forward to hosting a reception next month at the 64th Annual #ash22 hosted by @ASH_hematology to discuss the details of MP0533, our tetra-specific #darpin candidate for AML.
For further reception details and to RSVP visit: investors.molecularpartners.com/events/event-details/mole…
#hematology -
Molecular Partners
@MolecularPrtnrs
Our team members all share a universal passion for innovation, creativity, and collaboration to advance towards our common goal: to deliver differentiated potential treatments for patients through #darpins.
Learn about our openings: www.molecularpartners.com/careers/
#biotechjobs -
Molecular Partners
@MolecularPrtnrs
Our #radioligand programs harness the cancer-killing power of radioactive therapies with the high-affinity and high-specificity of #darpins, potentially enhancing tumor-specific delivery and greater tumor penetration.
Learn more: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Today we announced the presentation of positive interim results from our ongoing Phase 1 trial of MP0317 at @sitcancer’s 37th Annual Meeting. investors.molecularpartners.com/news-releases/news-releas… #sitc22
Post not available here, view on X
Molecular Partners
@MolecularPrtnrs
The development of CD40 agonists in #immunooncology has presented challenges due to dose-limiting toxicity, largely due to systemic CD40 activation.
Molecular Partners
@MolecularPrtnrs
These positive data support that MP0317’s mechanism is working as intended, with no dose limiting CD40-related systemic toxicities having been observed to date, and no signs of inflammatory cytokine release.
-
Molecular Partners
@MolecularPrtnrs
We look forward to presenting next month at the 64th Annual #ash22 event hosted by @ASH_hematology to discuss the details of MP0533, our tetra-specific #darpin candidate for AML.
Learn more about this upcoming presentation: investors.molecularpartners.com/news-releases/news-releas…
#hematology -
Molecular Partners
@MolecularPrtnrs
Today we announced that we will be presenting at @sitcancer’s Annual Meeting, @CreditSuisse’s Equity Forum, and @EvercoreISI’s HealthCONx Conference.
For further details, visit: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Tomorrow we are looking forward to kicking off the two-day long #festivalofbiologics in Basel, Switzerland! Our team will join other industry-leading experts to discuss next-generation approaches to #biologics.
Learn more at: www.terrapinn.com/conference/festival-of-biologics/Agenda… -
Molecular Partners
@MolecularPrtnrs
#darpins offer multiple unique advantages over other traditional approaches, including tunable half-life extension.
We harness this specific advantage across our #oncology and antiviral programs.
Check out further unique advantages of DARPins: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
Today we announced our third quarter interim management statement. Read more about our latest research and development, as well as financial, and clinical updates in our press release: investors.molecularpartners.com/news-releases/news-releas… $MOLN
-
Molecular Partners
@MolecularPrtnrs
Today we published our environmental, social & governance (#esg) corporate overview. Learn about our priorities where we believe we can make the greatest positive impact as global citizens committed to creating a #sustainable and healthy world.
Read more: investors.molecularpartners.com/environmental-social-and-… -
Molecular Partners
@MolecularPrtnrs
Check out our employee garden in Zürich! At Molecular Partners, our teammates love to step out of the office and put their green thumbs to use in this tranquil space.
#worklifebalance #swissbiotech -
Molecular Partners
@MolecularPrtnrs
Get to know our leader of employee strategy, culture, and collaboration, Renate Gloggner!
Renate ensures that our team empowers each other through internal collaboration as we collectively work towards pioneering a new class of medicines. -
Molecular Partners
@MolecularPrtnrs
#darpins can block multiple targets at once, making it difficult for a single mutation in a virus or cancer cell to break through. This could give our candidates broader efficacy and allow them to remain powerful against evolving targets.
Learn more:
www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
Our team is focused on pioneering a new class of biologic medicines with the goal of improving treatment options for patients with serious diseases.
We are always seeking new team members who share our passion for innovation.
Learn about our openings:
www.molecularpartners.com/careers/ -
Molecular Partners
@MolecularPrtnrs
We would like to congratulate to Anne Goubier on her promotion to SVP of Biology!
Dr. Goubier’s leadership has been a key element of our progress and we look forward to her continued support as we pioneer a new class of biologic medicines. -
Molecular Partners
@MolecularPrtnrs
#didyouknow that the binding surfaces of a #darpin exert a unique molecular ‘grip’ on their targets, allowing exquisite affinity and binding specificity, broadening the targetable epitope space for biologics.
Learn more about our DARPin platform: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
Today is #worldcancerresearchday. Our team is focusing on the power of our oncology programs to develop innovative therapeutics to support the unmet need for patients.
Learn more about our MP0317, MP0533, and other cancer programs:
www.molecularpartners.com/pipeline/
#cancerresearch -
Molecular Partners
@MolecularPrtnrs
Vladimir Kirkin is our Senior Director & Development Project Leader. Utilizing his proven drug development track record, Vladimir has a creative and strategic leadership approach, optimizing the innovative skills of our team as we develop a new class of medicines.
#meettheteam -
Molecular Partners
@MolecularPrtnrs
Our #darpin therapeutics have multiple advantages compared to other protein-based drugs. For one, thermal stability supports a potentially longer shelf-life and delivery of #darpin candidates to treat patients worldwide.
Learn more about our approach: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, we share a passion for innovation, creative thinking, and inspiration to do what we do for the difference our work can make for our patients.
Check out our current job openings and apply today: www.molecularpartners.com/careers/
#biotechjobs #darpins
#cancerresearch -
Molecular Partners
@MolecularPrtnrs
Last month our team spent a beautiful summer evening full of laughter, great food, and fun games, as we had the chance to “eat, meet, and chill!”
#worklifebalance -
Molecular Partners
@MolecularPrtnrs
September is #bloodcancerawareness Month. Our #acutemyeloidleukemia candidate is approaching Phase 1 trial initiation this year as we race to create solutions for #bloodcancer.
Read more about the design of our MP0533 #darpin program: www.molecularpartners.com/pipeline/
#fightbloodcancer -
Molecular Partners
@MolecularPrtnrs
DARPins
-
Molecular Partners
@MolecularPrtnrs
Our VP of Information Technology & Leader of Digitalization, Baris Arican, is a key member of our team. Baris is passionate about using his more than 20 years of industry experience to drive innovation & collaboration for us as we pioneer DARPins as a new class of medicines.
-
Molecular Partners
@MolecularPrtnrs
Today we recognize #womensequalityday. In this important moment in history, it is essential to reflect on what this day means and the need to support continued progress for #womensrights. We are dedicated to advancing the careers of #womeninscience across our team and the world.
-
Molecular Partners
@MolecularPrtnrs
Today we’re sharing corporate highlights and unaudited financial results for the first half-year of 2022. We will also be hosting a conference call and live webcast tomorrow at 8am ET (2pm CET). Read more on our results and how to join the call: investors.molecularpartners.com/news-releases/news-releas… $MOLN
-
Molecular Partners
@MolecularPrtnrs
Our team is working hard to deliver DARPins as a new class of medicines to patients across the globe.
#swissbiotech #biotechjobs -
Molecular Partners
@MolecularPrtnrs
#icymi: Earlier this year we shared preclinical data from our MP0317 program, our second in our localized #immunooncology pipeline to enter clinical studies.
We’re looking forward to progress in our #oncology platform in 2H 2022. Learn more: www.molecularpartners.com/pipeline/
Molecular Partners
@MolecularPrtnrs
Today we are pleased to announce the publication of preclinical data from MP0317 in @CIR_AACR. MP0317 is our second #immunooncology program to enter clinical studies.
Read more in our press release: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
#didyouknow: Our platform offers an extensive library of potential DARPin combinations that allow us to always be expanding our technical capabilities. We are continuously unlocking new aspects of our platform.
Learn more here: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
Today we wish our team in Switzerland and everyone a very happy #swissnationalday!
#didyouknow: The biopharma industry in Switzerland employs over 50,000 people and there are over 1,000 companies?
Learn more about our industry: www.swissbiotech.org/industry/
#swissbiotech -
Molecular Partners
@MolecularPrtnrs
Our DARPin candidates benefit from a high-yield bacterial manufacturing process that allows for a simpler and faster scale-up compared to other biologic medicines. Learn more about this and other benefits of our DARPin platform: www.molecularpartners.com/darpin-biology/
-
Molecular Partners reposted
Utrecht Virology Lab
@UtrechtVirology
We are delighted to announce the publication of our ensovibep paper @NatureBiotech! It's been a pleasure working with @MolecularPrtnrs (& many others) to develop a first-in-class, DARPin therapeutic for #covid19. Congratulations to everyone involved! 🎉
www.nature.com/articles/s41587-022-01382-3 -
Molecular Partners reposted
Utrecht Virology Lab
@UtrechtVirology
To learn more about the development of ensovibep, check out this nice blog by Michael Stumpp! 👇
bioengineeringcommunity.nature.com/posts/the-darpin-platf… -
Molecular Partners reposted
Nature Biotechnology
@NatureBiotech
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants go.nature.com/3B3oYaZ
-
Molecular Partners
@MolecularPrtnrs
Today we announced the publication in @NatureBiotech of key data detailing the unique design and mechanism of our COVID-19 antiviral candidate, now fully licensed by @Novartis. Learn more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Our DARPin platform can generate modular therapeutics that are fully customizable and have the potential to solve many of the complex biological challenges at the heart of many diseases: Learn more: www.molecularpartners.com/darpin-platform/
-
Molecular Partners
@MolecularPrtnrs
Earlier this month, Alexander Zürcher became our Chief Operating Officer after a successful tenure as our SVP of Development, where he oversaw project and portfolio management, manufacturing, pharmacology, and quality assurance activities
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, partners is in our name for a reason. Our growing team collaborates on a daily basis so we can meet our shared goals. Learn more about our mission and company culture: www.molecularpartners.com/careers/
-
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz was honored to once again judge Switzerland’s leading innovation contest, @ventureoffice Startup Competition. Congratulations to @enerdrape on the Grand Prize and to the other exciting companies who participated!
Read more: www.venture.ch/winners -
Molecular Partners
@MolecularPrtnrs
Our Vice President of Biology Anne Goubier will present our MP0533 program at the @VIBConferences’ “Recent insights into Immuno-Oncology” event this week. Learn more about the event here: www.vibconferences.be/events/recent-insights-into-immuno-…
#cancerresearch #immunooncology #immunoonc2022 -
Molecular Partners
@MolecularPrtnrs
The Molecular Partners team will be at the @IAmBiotech International Convention in San Diego this week to present a company overview.
-
Molecular Partners
@MolecularPrtnrs
Today we announced our programs will be presented at the @EHA_Hematology Conference, @ASMicrobiology 2022 and Dissecting Evolution and Heterogeneity of Single Cancer Cells, and that we gave a recent presentation at @AntibodyEngIC Europe. Read more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Today we recognize #nationalcancersurvivorsday and the determination of all those affected by cancer. The courage of patients and families motivates us in our mission to continue to advance our oncology programs to create a future with more survivors.
-
Molecular Partners
@MolecularPrtnrs
Anne Goubier, D.V.M., Ph.D. is our VP of Biology, bringing over two decades of biotech experience in both discovery and development to our team.
Learn more about our leadership team: www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
Our team is growing and we are seeking top scientific and operational talent to support our mission to pioneer a new class of biologic medicines.
Learn more about our open positions: www.molecularpartners.com/careers/ -
Molecular Partners
@MolecularPrtnrs
May is #nationalcancerresearch Month. Through our industry-leading platform, our team is dedicated to harnessing DARPins to treat cancer in novel ways.
Learn more about our programs: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz will present a company overview this week at @BioCentury's #bioequityeurope event. The presentation will be available on-demand and on our website: investors.molecularpartners.com/news-and-events/events $MOLN
-
Molecular Partners
@MolecularPrtnrs
Julia Hepp, Ph.D. is our Vice President of Partnering and Alliances, bringing more than two decades of experience to our team.
Learn more about our industry-leading DARPin science: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
Today at 9am ET Molecular Partners CEO Patrick Amstutz will participate in a Fireside chat at the 2022 @rbccm Global Healthcare Conference. $MOLN
-
Molecular Partners
@MolecularPrtnrs
Today we released our first quarter results. Learn more about our recent progress and upcoming plans: investors.molecularpartners.com/news-releases/news-releas… $MOLN
-
Molecular Partners
@MolecularPrtnrs
We are looking forward to presenting at the @rbccm Global Healthcare Conference and @Biocentury’s #bioequityeurope this month. Read more here: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Our CEO and new President of @swissbiotech Patrick Amstutz was honored to meet with so many people at the annual #swissbiotechday, including President of the Swiss Confederation @ignaziocassis. $MOLN
-
Molecular Partners
@MolecularPrtnrs
Congratulations to our CEO Patrick Amstutz on being named President of the @SwissBiotech Association Board of Directors.
In this role, he will continue to foster a culture of innovation among life science leaders to make an impact for patients together: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
DARPins’ small size gives the class some powerful advantages.
Even when linked together, our multi-specific candidates are one tenth the size of antibodies, allowing for the potential of greater tissue penetration.
Learn more: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
We recently announced a collaboration with @Novartis to develop DARPin-based radioligand therapies. By harnessing the power of radioactive atoms to apply to cancers, we can deliver targeted radiation to tumor cells, while sparing healthy tissue. See more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
A DARPin therapeutic candidate, which was in-licensed by @novartis in January 2022, has exhibited in vitro pan-variant neutralization activity against all known #covid19 variants of concern to-date.
Learn more about our COVID-19 program: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
#meettheteam Philippe Legenne is our VP, Clinical Development and External Scientific Relations. Philippe leads the clinical development and operations teams, as well as heading external scientific engagement. Learn more about us: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
We are pleased to announce that our shareholders have approved all board proposals at our Annual General Meeting.
Read more: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
We’re honored to partner with leading organizations who have recognized the potential of DARPins to deliver unique, therapeutic solutions for patients in need of novel treatments.
Learn more about our partnerships here: www.molecularpartners.com/partnering/ -
Molecular Partners
@MolecularPrtnrs
#icymi we recently shared the publication of preclinical data from MP0317, a DARPin therapeutic candidate in our #immunooncology pipeline in Cancer Immunology Research (@CIR_AACR). Read more: investors.molecularpartners.com/news-releases/news-releas…
Molecular Partners
@MolecularPrtnrs
Today we are pleased to announce the publication of preclinical data from MP0317 in @CIR_AACR. MP0317 is our second #immunooncology program to enter clinical studies.
Read more in our press release: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
#didyouknow DARPins can block multiple targets at once? A single mutation in a virus or cancer cell is not likely to overcome the multi-specificity of our DARPin candidates, potentially allowing for broader efficacy against evolving targets.
Read more: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
We recently shared positive Phase 2 data from our pan-variant DARPin antiviral candidate for #covid19. #didyouknow, our DARPin candidate can neutralize viral particles to prevent the infection of a target cell?
Learn more: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
Today we are pleased to announce the publication of preclinical data from MP0317 in @CIR_AACR. MP0317 is our second #immunooncology program to enter clinical studies.
Read more in our press release: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Today, we shared a poster at @ISARICAR #icar2022 conference highlighting that ensovibep has exhibited in vitro pan-variant neutralization activity against all known #covid19 variants of concern, including #omicron (BA.1 and BA.2 sub-variants). See more: investors.molecularpartners.com/static-files/4f832e01-83c…
-
Molecular Partners
@MolecularPrtnrs
Today we shared our 2021 Annual Report containing corporate highlights, research and development updates and audited financial results for the year. Read more in our press release: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
#dyk we can add special technical capabilities to any of our #darpin candidates? These include DARPins that bind to HSA that have the potential to increase our candidates’ half-lives.
Learn more about DARPin biology: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
#meettheteam Renate Gloggner is our Senior Vice President, Human Resources.
At Molecular Partners, we are dedicated to building a team around deep trust, individual diversity, and a shared passion for helping patients. Learn more about us: www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
We are pleased to be presenting at @CowenResearch's 42nd Annual Health Care Conference today. We are excited to discuss our DARPin antiviral and oncology candidates. See more: www.tdsecurities.com/ca/en
-
Molecular Partners
@MolecularPrtnrs
Today is International Women’s Day!
Last month, our team gave a presentation to local classes about the importance of gender equality in #stem education.
#womensday #iwd -
Molecular Partners
@MolecularPrtnrs
We stand in solidarity with the people of #ukraine who are victims of this terrible war.
Molecular Partners is donating CHF 150K to benefit Ukrainian citizens, and will match funds raised by our employees in the next 10 days up to an additional CHF 150K. #standwithukraine️ -
Molecular Partners
@MolecularPrtnrs
Today is Employee Appreciation Day. On behalf of our entire executive team, we want to thank our employees for the amazing work they do every day for patients in need. #eaw2022 #employeeappreciationday
-
Molecular Partners
@MolecularPrtnrs
This week we welcomed students from Kantonale Maturitätsschule für Erwachsene to talk about careers in #biotech. We were thrilled to help inspire the next generation of scientists. #stem #stemeducation
-
Molecular Partners
@MolecularPrtnrs
#icymi we recently announced an exciting new collaboration with @Novartis to develop DARPin-conjugated radioligand therapies for our #oncology program. Learn more here: investors.molecularpartners.com/news-releases/news-releas… #rlt
-
Molecular Partners
@MolecularPrtnrs
Our DARPin platform offers a vast library of potential DARPin combinations that are constantly working to expand our technical capabilities.
Learn more here: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
Today we’re attending the @SVBLeerink Global Healthcare Conference. We look forward to connecting with fellow industry experts and institutional investors to discuss trends that are shaping the future of #healthcare and #technology. More here: leerink.com/events/
-
Molecular Partners
@MolecularPrtnrs
Today we are celebrating the International Day of Women and Girls in Science, dedicated to recognizing the importance of #science and #genderequality. We are joining the global initiative to inspire women who have been historically underrepresented in the #stem field.
Post not available here, view on X
Molecular Partners
@MolecularPrtnrs
“Science is beautiful and exciting; problems can be solved, and each solution brings a new question. At Molecular Partners, we are driven to find solutions for patients who need them, keeping teamwork at heart and scientific excellence in mind.” - Laura Jeanbart #womeninscience
Molecular Partners
@MolecularPrtnrs
“I like science because it is like solving an endless, fascinating riddle. You and others have to invest a lot of time and energy. But doing this with the aspiration of helping patients in need is more than rewarding and justifies all the efforts.” – Julia Ahlskog #womeninscience
-
Molecular Partners
@MolecularPrtnrs
Our multi-specific candidate for #aml combines DARPins that target cancer cells in 3 places, giving it the potential to deliver a deeper attack on a broader range of highly variable tumor cells while lowering the risk of off-target toxicity: www.molecularpartners.com/pipeline/ #oncology
-
Molecular Partners
@MolecularPrtnrs
Today we announced that our partner @Novartis has requested Emergency Use Authorization from the @US_FDA for ensovibep, our DARPin #antiviral therapeutic candidate to treat #covid19. Read more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Ensovibep is designed to simultaneously bind the #covid19 virus in 3 places.
We recently shared positive results from our global study of ensovibep in patients demonstrating 78% reduction of the risk of hospitalization, emergency room visits, or death: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Our multi-specific COVID-19 antiviral candidate was designed by our team in six weeks.
Learn more about our highly modular platform and how we can rapidly design multi-functional candidates for complex disease: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
#dyk the binding surfaces of a #darpin uniquely grip to challenging targets with high affinity, allowing them to strongly bind to certain proteins that antibodies struggle with? Learn more here: www.molecularpartners.com/darpin-platform/
-
Molecular Partners
@MolecularPrtnrs
Our DARPin platform has the potential to address a wide range of diseases, including #oncology, #ophthalmology, and #infectiousdiseases.
Explore our pipeline: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Our team draws on a vast library of trillions of different DARPin molecules to find those that bind best to different targets. Using multiple screens, we are then able to identify candidates with the highest target affinity. Learn more: www.molecularpartners.com/darpin-biology/
-
Molecular Partners
@MolecularPrtnrs
Our DARPin candidates are designed to benefit from high-yield manufacturing. They are produced through bacterial fermentation, a simple process that has major advantages over how antibodies are produced.
Learn more: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
@MolecularPrtnrs CEO Patrick Amstutz joining as a guest on today’s live conversation. Come listen!
Biotech Hangout
@BiotechCH
Need a quick way to catch up on all the news from this week? Join us this Sunday at 4pm ET to listen live and ask your questions!
Brad Loncar
@bradloncar
The newsmakers of #jpm22 will be joining us on Sunday for @BiotechCH.
💥 $BEAM @john_evans3
💥 @ArrakisTx @michael_gilman
💥 $MOLN Patrick Amstutz
Hope you can join us too!
@cngarabedian @daphnezohar
www.clubhouse.com/event/m3G3Glzv -
Molecular Partners reposted
Brad Loncar
@bradloncar
The newsmakers of #jpm22 will be joining us on Sunday for @BiotechCH.
💥 $BEAM @john_evans3
💥 @ArrakisTx @michael_gilman
💥 $MOLN Patrick Amstutz
Hope you can join us too!
@cngarabedian @daphnezohar
www.clubhouse.com/event/m3G3Glzv -
Molecular Partners reposted
Novartis
@Novartis
“The world’s arsenal of treatments against Covid-19 variants might become a bit stronger with a new antiviral that Novartis is developing”
Our agreement with @MolecularPrtnrs also includes manufacturing scale-up and plans to expedite access globally.
$NVS $NOVN #jpmhc22
Bloomberg
@business
Novartis is developing the first antiviral that attacks the coronavirus’s spike protein in not just one, but multiple ways www.bloomberg.com/news/newsletters/2022-01-12/a-new-antiv…
-
Molecular Partners
@MolecularPrtnrs
#icymi ensovibep maintains full neutralization of the #covid19 variant #omicron in in vitro studies. We designed ensovibep to outsmart future viral mutations, by harnessing our leading DARPin platform. Read more in our recent press release: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Here at Molecular Partners, we’re pioneering DARPins as a new class of medicines.
So what is a #darpin? We’re glad you asked:Post not available here, view on X
Molecular Partners
@MolecularPrtnrs
With the binding strength of the best antibodies and the ability to be rapidly screened during drug discovery, we’re bringing an entirely new dimension to biologic drug development.
Molecular Partners
@MolecularPrtnrs
Since our first groundbreaking discovery, we’ve remained at the forefront of the field, uncovering DARPins’ ever-expanding set of combinatorial capabilities.
Learn more about our industry-leading platform: www.molecularpartners.com/darpin-platform/ -
Molecular Partners reposted
Novartis España
@NovartisSpain
Junto a @MolecularPrtnrs hemos desarrollado un tratamiento contra la COVID-19 que ha obtenido resultados positivos, alcanzando el objetivo principal de reducir la carga viral durante 8 días y el riesgo de hospitalización en un 78%. #reimaginarlamedicina
👉www.novartis.com/es-es/news/media-releases/novartis-y-mol… -
Molecular Partners
@MolecularPrtnrs
Our DARPin antiviral candidate can simultaneously bind the #covid19 virus in 3 places, maximizing its activity against viral variants and preventing escape mutations.
Read more about the positive topline results from our Phase 2 global clinical trial: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Thank you to @VasNarasimhan and all our partners @Novartis for your support of DARPin innovation in the pursuit of new #covid19 therapies.
Vas Narasimhan
@VasNarasimhan
.@Novartis helped develop a potential new treatment option for COVID-19. Proud to continue our collaboration with Molecular Partners to pursue the kind of biomedical innovation that will help bring this pandemic to an end. More on today’s news: www.novartis.com/coronavirus
-
Molecular Partners
@MolecularPrtnrs
We are very proud to be collaborating with @NovartisNews @NovartisGH on this important program
Novartis Global Health
@NovartisGH
This new potential treatment for #covid19 patients provides risk reduction in hospitalizations and/or ER visits or death. We are quite encouraged by the topline data and look forward to our collaboration with @MolecularPrtnrs.
Novartis News
@NovartisNews
Today, with @MolecularPrtnrs, we are excited to announce a positive top line data from a Phase 2 study for a #covid19 antiviral treatment.
Novartis will exercise its option to in-license this therapeutic candidate from Molecular Partners.
#novartisnews -
Molecular Partners reposted
Novartis News
@NovartisNews
Today, with @MolecularPrtnrs, we are excited to announce a positive top line data from a Phase 2 study for a #covid19 antiviral treatment.
Novartis will exercise its option to in-license this therapeutic candidate from Molecular Partners.
#novartisnews -
Molecular Partners
@MolecularPrtnrs
We are excited to announce positive topline results from the global Phase 2 trial of our pan-variant DARPin antiviral candidate for #covid19 patients. investors.molecularpartners.com/news-releases/news-releas… $MOLN $NVS #jpm22
Molecular Partners
@MolecularPrtnrs
We are encouraged by our candidate’s potential to save lives and ease the burden of #covd19 on healthcare systems globally. Our thanks to our collaborator @Novartis. We will be holding a hold a conference call and audio webcast on Monday, Jan. 10 at 7am ET.
-
Molecular Partners
@MolecularPrtnrs
We are pleased to share our publication in @biorxivpreprint detailing a comprehensive study of ensovibep’s full inhibitory potency against all #covid19 variants of concern, including Omicron, as of December 2021. Read more here: www.biorxiv.org/content/10.1101/2021.02.03.429164v3 #omicron
-
Molecular Partners reposted
Jay Bradner, M.D.
@jaybradner
Imagining the next generation of radioligand therapies, the @MolecularPrtnrs DARPINs are just the peanut butter to go with our radioactive Swiss chocolate. Two great tastes that go great together.
-
Molecular Partners
@MolecularPrtnrs
#icymi we recently hosted our virtual Oncology Day. We were thrilled to be joined by 125 attendees this year and share our strategy for portfolio growth and expansion. Watch the recorded presentation here: investors.molecularpartners.com/news-and-events/events
-
Molecular Partners
@MolecularPrtnrs
Today is our virtual Oncology Day! We’re looking forward to connecting with our key stakeholders and investors as we share pipeline updates and our long term #darpin development strategy. Tune in here at 8:30 AM ET: onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!… #immunooncology
-
Molecular Partners
@MolecularPrtnrs
Today we are excited to announce a collaboration with @Novartis to develop, manufacture and commercialize DARPin-conjugated radioligand therapies for oncology. Read more in our press release: investors.molecularpartners.com/news-releases/news-releas… #rlt
-
Molecular Partners
@MolecularPrtnrs
This week, join our management team and leading #aml experts at our virtual Oncology Day on Wednesday December 15 at 8:30 AM ET! We’ll walk through our #darpin development strategy and share updates on our immuno-oncology programs. Register here: onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!…
-
Molecular Partners
@MolecularPrtnrs
We have confirmed that ensovibep maintains its full, high potency in neutralizing #omicron in the laboratory as it has against every viral variant of concern to-date. Read more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
On Wednesday December 15 at 8:30 AM ET we will host our virtual Oncology Day! We look forward to discussing our platform updates and strategy for portfolio growth and expansion. Register here: onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!… #immunooncology
-
Molecular Partners
@MolecularPrtnrs
Today we issued a statement regarding the recently identified #covid19 variant, Omicron. Ensovibep, our lead antiviral candidate in our COVID-19 program, maintains its potency against all relevant individual positions mutated in the Omicron variant. More: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz will participate in a fireside chat at the 4th Annual #evercore ISI #healthconx Conference. We look forward connecting with industry peers and discussing the latest progress of our pipeline and DARPin platform. Read more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
Next month we’ll be hosting a virtual Oncology Day on December 15. We look forward to sharing updates to our immuno-oncology portfolios and DARPin development strategy. Register here: onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!… #covid19 #immunooncology
-
Molecular Partners
@MolecularPrtnrs
Today we provided an update from the ACTIV-3 global clinical study evaluating ensovibep as a treatment for COVID-19 for patients who have been hospitalized with the disease. Learn more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
We are thrilled to announce the start of the clinical phase of MP0317, the second DARPin therapeutic candidate in our #immunooncology pipeline.
Read more in today’s release: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
Today we shared our third quarter interim management statement. Read more about our research and development, financial, and clinical updates: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
#meettheteam Alexander Zürcher is our SVP Development who oversees manufacturing, pharmacology, quality assurance, project management and portfolio management activities.
Learn more about our team: www.molecularpartners.com/about-us/ #biotechjobs -
Molecular Partners
@MolecularPrtnrs
#didyouknow our DARPin® platform has the ability to rapidly create multi-functional candidates?
Learn more about the advantages of DARPin biology: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
Today we announced the presentation of data describing the successful viral inhibitory capabilities of ensovibep against #covid19 variants of concern at the @IsirvEpi and @WHO COVID-19, Influenza and RSV virtual conference. Read more: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
#icymi ensovibep for #covid19 is the lead candidate in our #infectiousdisease program, currently in global phase 2/3 studies.
See the latest update on ensovibep’s progression through the clinic: investors.molecularpartners.com/news-releases/news-releas…
Molecular Partners
@MolecularPrtnrs
Our lead DARPin® candidate against #covid19 ensovibep is currently being assessed in three ongoing clinical trials. To date, ensovibep has shown full inhibition of all known #covid19 variants of concern, including the #deltavariant.
See more: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Our DARPin® platform can deliver precise anti-tumor attack through combining an immune-stimulating DARPin with a DARPin that localizes the immune activation to the tumor environment.
Learn more about DARPin advantages here: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz will be presenting at the @GDInstitute New Paths of Medicine conference today discussing the importance of DARPin® biology in the age of #covid19. See more information here: fuw-forum.ch/konferenz/health-2-021/
-
Molecular Partners
@MolecularPrtnrs
Tomorrow, our CEO Patrick Amstutz will be presenting at the @GDInstitute New Paths of Medicine conference. See the full agenda here: fuw-forum.ch/konferenz/health-2-021/
-
Molecular Partners
@MolecularPrtnrs
Collaboration is core to our work. Together, our team of highly motivated scientists have pioneered our unique DARPin® platform to go beyond the limits of today’s leading treatments.
Learn more about our mission: www.molecularpartners.com -
Molecular Partners
@MolecularPrtnrs
Our team is made up of passionate professionals who are dedicated to developing life transforming therapies for those in need. Learn more about us: www.molecularpartners.com/about-us/ #biotechjobs #team
-
Molecular Partners
@MolecularPrtnrs
Ensovibep is our lead candidate against #covid19. Learn more about our infectious disease program here: www.molecularpartners.com/pipeline/ #darpin #biotechnology
Molecular Partners
@MolecularPrtnrs
Our lead DARPin® candidate against #covid19 ensovibep is currently being assessed in three ongoing clinical trials. To date, ensovibep has shown full inhibition of all known #covid19 variants of concern, including the #deltavariant.
See more: www.molecularpartners.com/pipeline/
Molecular Partners
@MolecularPrtnrs
And see our manuscript submission in
@biorxivpreprint for a summary of our #covid19 research including preclinical potency, candidate design and in vivo data: www.biorxiv.org/content/10.1101/2020.08.25.256339v1.
#darpin #biotechnology -
Molecular Partners
@MolecularPrtnrs
MeetTheTeam Michael Stumpp, Ph.D., is COO and co-founder of Molecular Partners. Michael was part of the team that invented the DARPin® technology that our company was built on.
Learn more about us: www.molecularpartners.com/about-us/ #biotechjobs -
Molecular Partners
@MolecularPrtnrs
One key advantage to our DARPin® biology approach is that #darpins are smaller in size than other types of medicines, allowing for greater tissue penetration across a wide variety of applications.
Learn more: www.molecularpartners.com/darpin-biology/ #darpin #biotechnology -
Molecular Partners
@MolecularPrtnrs
This week our CEO joined a jury of experts to determine the winner of @ventureoffice, Switzerland’s leading startup competition. Congratulations @MapTiler! As former recipients of this award, we are thrilled to support the next generation of Swiss biotech & fellow innovators.
-
Molecular Partners
@MolecularPrtnrs
September is #bloodcancerawareness month and we are working on a new approach to treating one major blood cancer, AML, that could have a meaningful impact on the lives of cancer patients.
Molecular Partners
@MolecularPrtnrs
Our therapeutic candidate for AML aims to leverage the T-cell protein CD3 as a powerful immune activator against cancer. It also targets three different tumor associated antigens commonly found in combination on leukemic cells.
Molecular Partners
@MolecularPrtnrs
This highly specific triple-targeting approach is designed to unleash an immune attack preferentially to cancer cells, potentially reducing harmful side effects, which have historically limited the power of CD3 activation.
Learn more about our pipeline: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Recently, we expanded our pipeline to include infectious diseases. #didyouknow, our DARPin® candidates can neutralize viral particles to prevent the infection of a target cell?
Learn more: www.molecularpartners.com/darpin-platform/ #darpin #biotechnology #covid19 #infectiiousdisease -
Molecular Partners
@MolecularPrtnrs
We are inventors and developers of an entirely new class of therapeutics. We are highly collaborative: with our team, our partners, and the patients and providers we work with every day.
Learn more about us: www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
#icymi in June we publicly listed as a U.S. company, and we are thrilled to embark on our next chapter. Our long-term strategy leverages our DARPin® design and development expertise with the capabilities of world-class partners to deliver a broad pipeline of therapeutics.
Molecular Partners
@MolecularPrtnrs
Today we were proud to celebrate our recent U.S. listing with @Nasdaq. Since our founding, we have advanced a new class of medicines for patients and look forward to writing the next chapter for DARPin® therapeutics. Read more: www.molecularpartners.com/molecular-partners-announces-pr… #$MOLN
-
Molecular Partners
@MolecularPrtnrs
Our lead DARPin® candidate against #covid19 ensovibep is currently being assessed in three ongoing clinical trials. To date, ensovibep has shown full inhibition of all known #covid19 variants of concern, including the #deltavariant.
See more: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Today we’re pleased to share corporate highlights and unaudited financial results for the first half-year of 2021. Read more about our therapeutic programs, research and development, and milestones to date: investors.molecularpartners.com/news-releases/news-releas…
-
Molecular Partners
@MolecularPrtnrs
CD3-targeted T-cell engagement is a very successful anti-tumor approach. However recent candidates have struggled with toxicity. Our unique DARPin® candidates could offer a solution.
Learn more about our pipeline: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
#dyk our DARPin® candidates are designed to benefit from high-yield manufacturing? They are produced through bacterial fermentation, a simple process that is a major advantage over other approaches.
Learn more: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
Our unique DARPin® technology can block multiple targets at once. No single mutation in a virus, like #covid-19, is likely to break through, giving our candidates potentially broader efficacy.
Learn more: www.molecularpartners.com/darpin-platform/ -
Molecular Partners
@MolecularPrtnrs
#meettheteam Julia Hepp is our Vice President, Partnering & Alliances. Julia brings two decades of #biotech experience in research and development, alliance management and business development.
Learn more about our team: www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
What is a DARPin®? DARPin® therapeutics are protein-based drugs that have multiple unique advantages that differentiate them from other protein-based drugs, opening up numerous opportunities for treating serious diseases.
Learn more: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
There remains a significant need for optimized therapies for patients with retinal diseases. Today we announced we regained the global rights to abicipar, a registrational-stage candidate for the treatment of nAMD and diabetic macular edema.
Learn more: investors.molecularpartners.com/news-releases/news-releas… -
Molecular Partners
@MolecularPrtnrs
We have continuously expanded the capabilities of our DARPin® candidates to generate customizable therapeutics with the potential to solve many complex biological challenges at the heart of disease: www.molecularpartners.com/darpin-platform/
-
Molecular Partners
@MolecularPrtnrs
Our DARPin® therapeutic programs offer many unique advantages over other traditional approaches, including tunable half-life extension. Learn more about DARPin® capabilities: www.molecularpartners.com/darpin-platform/
-
Molecular Partners
@MolecularPrtnrs
#icymi our lead antiviral candidate ensovibep maintained potency in the lab and demonstrated full inhibition of all newly emerging known #covid19 variants of concern, including the #deltavariant. Read more in our press release: investors.molecularpartners.com/news-releases/news-releas…
Molecular Partners
@MolecularPrtnrs
For a broader history of ensovibep’s development and our antiviral program, check out our detailed manuscript in @biorxivpreprint: www.biorxiv.org/content/10.1101/2021.02.03.429164v2.full #covid19
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, we draw on a vast library of trillions of different DARPin® molecules to find those that bind best to molecular targets. Single DARPin® molecules can be combined in multiple ways to provide tailored effects.
Learn more: www.molecularpartners.com/darpin-biology/ -
Molecular Partners
@MolecularPrtnrs
MP0317 is a DARPin® candidate in our #immunooncology pipeline designed to activate immune attack specifically on tumor cells through a unique mechanism. Learn more: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
We’re excited to share our updated website! Learn more about our DARPin® platform, pipeline, team and mission: www.molecularpartners.com
-
Molecular Partners
@MolecularPrtnrs
Today we were proud to celebrate our recent U.S. listing with @Nasdaq. Since our founding, we have advanced a new class of medicines for patients and look forward to writing the next chapter for DARPin® therapeutics. Read more: www.molecularpartners.com/molecular-partners-announces-pr… #$MOLN
-
Molecular Partners
@MolecularPrtnrs
We’re pleased to announce that a first patient has been dosed in the NIH-sponsored ACTIV-3 trial assessing ensovibep for the treatment of #covid19, and that ensovibep received a U.S. FDA Fast Track designation. Read more: www.molecularpartners.com/molecular-partners-announces-fi…
-
Molecular Partners
@MolecularPrtnrs
Today we announced initiation of the global phase 2/3 EMPATHY clinical study of ensovibep as a novel antiviral against #covid19. EMPATHY is conducted by our partner @Novartis and seeks to enroll 2,100+ patients in the ambulatory setting. Read more: www.molecularpartners.com/novartis-and-molecular-partners…
-
Molecular Partners
@MolecularPrtnrs
Today we announced our #covid19 candidate ensovibep continues to retain full potency against emerging viral variants of SARS-CoV-2, based on new laboratory studies. Read more: www.molecularpartners.com/molecular-partners-covid-19-ant…
-
Molecular Partners
@MolecularPrtnrs
This week, we’re looking forward to presenting four posters with data supporting three of our immunotherapy programs at the @AACR Virtual Annual Meeting. See more: www.molecularpartners.com/molecular-partners-shares-new-d…
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, our team members are each uniquely driven to advance our DARPin platform and broad pipeline of innovative therapies. Learn more: www.molecularpartners.com
-
Molecular Partners
@MolecularPrtnrs
Today we announced the nomination of Dominik Höchli, M.D. to our Board of Directors, proposed for election at the April 21 Annual General Meeting. Dominik has an extensive skill set and 20 years of experience as a marketing & medical affairs executive. www.molecularpartners.com/molecular-partners-nominates-do…
-
Molecular Partners
@MolecularPrtnrs
#icymi we recently shared an update to our #covid19 program. The study design and results were published on the research preprint service @biorxivpreprint. Read more here: www.biorxiv.org/content/10.1101/2021.02.03.429164v1 & see latest press release here: www.molecularpartners.com/molecular-partners-and-novartis…
-
Molecular Partners
@MolecularPrtnrs
#meettheteam Robert Hendriks is Vice President of Finance at Molecular Partners. Robert brings deep financial leadership expertise to our team and has over 15 years of international financial management experience. Learn more about us: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
We are pleased to announce the planned inclusion of ensovibep in ACTIV-3, a global phase 3 clinical trial, as part of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. Read more in today’s press release: www.molecularpartners.com/molecular-partners-novartis-ann…
-
Molecular Partners
@MolecularPrtnrs
Today we announced the nomination of Agnete Fredriksen to our Board of Directors, proposed for election at the April 21 Annual General Meeting. Agnete is a scientist-entrepreneur with experience building novel platforms into global biopharma. Read more: www.molecularpartners.com/molecular-partners-nominates-ag…
-
Molecular Partners
@MolecularPrtnrs
Today we announced the upcoming presentation of data supporting three of our unique immunotherapy approaches at the @AACR Virtual Annual Meeting on April 10-15. Read more in today’s press release: www.molecularpartners.com/molecular-partners-to-present-d…
-
Molecular Partners
@MolecularPrtnrs
Today, we and @Novartis announced preliminary results from our ongoing phase 1 study of our first tri-specific #covid19 antiviral treatment, ensovibep, showing it to be safe and well tolerated with no significant reported adverse events. See more: www.molecularpartners.com/molecular-partners-and-novartis…
-
Molecular Partners
@MolecularPrtnrs
Today is Employee Appreciation Day! At Molecular Partners, we are proud to work with a team of passionate professionals who are dedicated to transforming the lives of people with serious diseases. Learn more about us: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
Today we shared corporate highlights and unaudited financial results for 2020. Read more about our recent research and development updates and key financials here: www.molecularpartners.com/3326-2/
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, collaboration is at the core of our work. We build on deep trust, individual diversity, and shared passion to reach our common goal of surmounting the toughest challenges in medicine, cancer, and other serious diseases. Learn more: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
#meettheteam Seth Lewis is Senior Vice President, Investor Relations, Communications & Strategy at Molecular Partners. His work includes global communications, shareholder relationship management and external strategy. Learn more about our leadership team: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
Our unique DARPin drug class has allowed us to develop an expansive portfolio with vast applicability across a range of diseases. Learn more about our pipeline: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
Today we are celebrating the International Day of Women and Girls in Science. Our team is joining the @UN and the global community to inspire women and girls who have been historically underrepresented in science, technology, engineering and mathematics. #womeninscience #stem
Molecular Partners
@MolecularPrtnrs
Our scientific team at Molecular Partners is over 60% women who lead in translational and medical R&D, oncology, and infectious diseases, focused on global threats and life-threatening diseases. #womeninscience
Molecular Partners
@MolecularPrtnrs
Throughout the day, we will highlight a few of the #womeninscience on our team here at Molecular Partners, please meet our colleagues!
We also encourage you to visit the official @WomenScienceDay page for more information and resources: womeninscienceday.org
#stemPost not available here, view on X
Molecular Partners
@MolecularPrtnrs
“I moved into science because I believe there is no other discipline with the infinite potential of exploring new things. MP fosters this spirit of breaking new ground and being courageous in transforming ideas into novel therapeutics” –Nina Reschke @nina250710 #womeninscience
Molecular Partners
@MolecularPrtnrs
“The continuing curiosity to understand the how and why in order to develop new medicines motivates me every day”
- Sophie Barsin #womeninscience -
Molecular Partners
@MolecularPrtnrs
#icymi we attended and presented at a number of investor healthcare conferences recently. See our presentation recordings here: investors.molecularpartners.com/investor-and-scientific-d…
-
Molecular Partners
@MolecularPrtnrs
Yesterday we announced promising results from a study of ensovibep & MP0423, against new variants of #covid19, including those initially identified in the UK and South Africa, showing therapeutic activity on all tested viral variants. Read more: www.molecularpartners.com/molecular-partners-and-novartis…
-
Molecular Partners
@MolecularPrtnrs
#meettheteam Andreas Emmenegger has been CFO of Molecular Partners since 2007. Andreas has served as CFO of several public and private multinational companies, mostly in the #biotech industry. Learn more about us: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
Today we will be participating in the 2021 Octavian Seminar. Details here: www.clariant.com/en/Corporate/Events/2021/01/Octavian-Sem…
-
Molecular Partners
@MolecularPrtnrs
Today we are presenting at the JP Morgan 39th Annual Virtual Healthcare Conference. See the webcast here: investors.molecularpartners.com/investor-and-scientific-d…
-
Molecular Partners
@MolecularPrtnrs
We were pleased to present at the Baader Helvea Swiss Equities Conference today. Details here: www.swissequitiesconference.com
-
Molecular Partners
@MolecularPrtnrs
We recently announced first data from our ongoing phase 1 first-in-human study of DARPin® candidate, MP0420 (ensovibep), as part of our collaboration with Novartis. Read more about this unique therapeutic program here: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
Today we announced that Molecular Partners will be presenting at several upcoming healthcare investor conferences. See the details in today’s release: www.molecularpartners.com/molecular-partners-to-present-a…
-
Molecular Partners
@MolecularPrtnrs
#happynewyear! As we welcome 2021, we are grateful to the MP team, our stakeholders & our partners for their continued support. We look forward to continue advancing our pipeline programs & building our differentiated DARPin platforms for the benefit of patients in the new year.
-
Molecular Partners
@MolecularPrtnrs
#dyk our DARPin® therapeutics display favorable development properties, including low-cost high-yield manufacturing? These features make our DARPin® approach ideally suited for antiviral therapies, particularly during this time of global need.
-
Molecular Partners
@MolecularPrtnrs
This year, we have unlocked and expanded the reach of DARPins to rapidly respond to #covid-19, advance our oncology portfolio and deliver new discovery platforms for the potential benefit of patients worldwide. Read more: www.molecularpartners.com/molecular-partners-announces-ne…
Post not available here, view on X
Molecular Partners
@MolecularPrtnrs
Data from the ongoing phase 1 study of MP0310 (AMG 506) demonstrate a tumor-localized immune engagement, per design, and a strong tolerability profile. Read more about this @Amgen-partnered I/O program here: www.molecularpartners.com/pipeline/
Molecular Partners
@MolecularPrtnrs
In discovery, we have advanced our ability to design candidates that modulate the immune system in two cutting-edge ways, offering novel possibilities for a range of diseases. Hear more about CD-3 T cell engagers and pMHC binders within our presentation: onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!…
-
Molecular Partners
@MolecularPrtnrs
Today is Molecular Partners’ R&D Day! We will be sharing our vision for an exciting new chapter in our story as well as multiple milestones across our portfolio. Tune in here: onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!…
-
Molecular Partners
@MolecularPrtnrs
We will be hosting our virtual R&D Day for investors and analysts on December 17th starting at 9:00 a.m. ET. Register here: onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!…
-
Molecular Partners
@MolecularPrtnrs
Thomas Schwerzmann is our VP Human Resources. Since joining Molecular Partners, Thomas has built up our HR department to support our expediated growth and brings a diverse global & functional human resources background to our team. Learn more: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
MP0317 is the second DARPin® protein in our immuno-oncology pipeline and is designed to act as an #immunotherapy that activates immune cells solely in tumors, allowing for super-activation while avoiding systemic side effects. Learn more: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
Today we announced that we will host a virtual R&D Day at 9:00 a.m. ET on Thursday, December 17. We look forward to sharing updates to our oncology program, preliminary data from the Phase 1 study of MP0420, and our recent portfolio updates. See more: www.molecularpartners.com/molecular-partners-to-share-cli…
-
Molecular Partners
@MolecularPrtnrs
Our unique tri-specific DARPin® candidates, MP0420 & MP0423 exhibit among the strongest #covid19 virus inhibition potency reported to date and potential efficacy in both prophylactic and post exposure settings. Learn more about our program: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
#meettheteam Julien Gander is our General Counsel, VP Legal for Molecular Partners. He is also Secretary of the Board of Directors and brings over a decade of experience in various corporate law positions to our team. Learn more about us: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
Today we announced dosing of the first cohort in a Phase 1 study of our #covid19 DARPin® therapeutic candidate, MP0420 (ensovibep), as part of our collaboration with @Novartis. MP0420 has potential as both a prophylactic and treatment. See more: www.molecularpartners.com/molecular-partners-doses-first-…
-
Molecular Partners
@MolecularPrtnrs
We have made several advancements to our #covid19 DARPin® program over the past few months. Candidate design and preclinical potency data are detailed in our recently submitted manuscript to @biorxivpreprint. Read here: www.biorxiv.org/content/10.1101/2020.08.25.256339v1
-
Molecular Partners
@MolecularPrtnrs
Each member of our team is uniquely driven and deeply motivated to improve the options available to people with cancer. Learn more about us: www.molecularpartners.com
-
Molecular Partners
@MolecularPrtnrs
We tackle medical need with custom-built protein biologics. Our DARPin® module library contains 10¹² individual members that are able to adapt their binders to any given target with the same affinity and specificity as the best antibodies. Learn more: www.molecularpartners.com/our-darpin-platform/
-
Molecular Partners
@MolecularPrtnrs
#icymi we recently announced a collaboration with @Novartis to advance our #covid19 DARPin® program. We expect to initiate first-in-human clinical trials this month. Learn more: www.molecularpartners.com/molecular-partners-announces-co…
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, each member of our team is uniquely driven to improve the treatment options available to people with cancer. Learn more about what motivates us: www.molecularpartners.com
-
Molecular Partners
@MolecularPrtnrs
Today we shared financial and operational corporate highlights for the period ending September 30, 2020. Read more about our recent research, drug development efforts and therapeutic programs here: www.molecularpartners.com/interim-management-statement-q3…
-
Molecular Partners
@MolecularPrtnrs
Today we announced a collaboration with @Novartis to accelerate development of our DARPin® candidates for #covid19, MP0420 & MP0423. First-in-human clinical trials are planned for November 2020. Read more in today’s press release: www.molecularpartners.com/molecular-partners-announces-co…
-
Molecular Partners
@MolecularPrtnrs
#icymi we announced the completion of initial GMP manufacturing runs for our #covid19 DARPin® candidate, MP0420 last month. Human studies are planned to begin in November 2020. Read more here: www.molecularpartners.com/molecular-partners-completes-gm…
-
Molecular Partners
@MolecularPrtnrs
#meettheteam Michael Tobias Stumpp is COO and co-founder of Molecular Partners. Michael was part of the team that invented our DARPin® technology. Learn more about us: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
DARPin® therapeutics are small in size compared to monoclonal antibodies, allowing for greater tissue penetration. Learn more about the advantages of our DARPin® candidates: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
Today we shared promising in vivo data from our #covid19 DARPin® candidates, supporting MP0420 and MP0423 as potential therapeutic options for patients with severe and late-stage disease. Read more: www.molecularpartners.com/molecular-partners-demonstrates…
-
Molecular Partners
@MolecularPrtnrs
#icymi we have made significant manufacturing advancements for our #covid19 program. Read here: www.molecularpartners.com/molecular-partners-completes-gm… and learn more about our unique approach for tackling the pandemic here: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
Meet Alexander Zürcher, our SVP of Development. Alexander oversees manufacturing, bioanalytics, pharmacology, clinical operations & quality assurance activities at Molecular Partners. Learn more about us: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
#icymi our team recently submitted a manuscript to the research forum @biorxivpreprint, detailing our #covid19 research including preclinical potency, candidate design and in vivo data. We are so proud to be a part of this journey! Read the draft here: www.biorxiv.org/content/10.1101/2020.08.25.256339v1
-
Molecular Partners
@MolecularPrtnrs
Today we presented preclinical data at the Annual World Bispecific Summit supporting the tumor localizing mechanism of MP0317, our tri-specific DARPin® in development to fight cancer, which includes binding domains for the proteins FAP and CD40. Read more: www.molecularpartners.com/molecular-partners-presents-pre…
-
Molecular Partners
@MolecularPrtnrs
#dyk our DARPin® drug class has a range of favorable properties including rapid high-yield manufacturing, long shelf-life, and greater stability? DARPins can also be stored for years at 4°C, simplifying supply chain management. Learn more: www.molecularpartners.com/our-darpin-platform/
-
Molecular Partners
@MolecularPrtnrs
#icymi we recently announced several advancements to our anti #covid19 program, including an agreement with @BAG_OFSP_UFSP and supportive in vivo data. Learn more about our COVID19 DARPin candidates: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
Today we announced the completion of initial GMP manufacturing runs for our #covid19 DARPin® candidate, MP0420. First-in-human studies are planned to begin in November 2020. Read more: www.molecularpartners.com/molecular-partners-completes-gm…
-
Molecular Partners
@MolecularPrtnrs
Our CEO Patrick Amstutz will be participating in the @HCWCO 22nd Annual Global Investment Conference and @MorganStanley Virtual Global Healthcare Conference to discuss our recent pipeline progress and #covid-19 DARPin® program.
Live webcasts here: investors.molecularpartners.com/investor-and-scientific-d… -
Molecular Partners
@MolecularPrtnrs
#covid19 represents the biggest disease burden in the world today. Our unique, tri-specific DARPin® candidates have shown cooperative target binding and exhibit among the strongest virus inhibition potency reported to date. Read more about this program: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, our team shares a common goal: to go beyond the limits of today’s leading treatments for cancer and pioneer an entirely new class of custom-built medicines. Learn more about our approach: r.socialstudio.radian6.com/8750c3da-2b10-4cd7-8c21-2d7bc1…
-
Molecular Partners
@MolecularPrtnrs
Mono-DARPins are the building blocks for multi-functional DARPin® candidates. They allow for rapid development of custom-built protein therapeutics to address a wide range of diseases. Learn more: www.molecularpartners.com/our-darpin-platform/
-
Molecular Partners
@MolecularPrtnrs
#icymi @PharmaScrip recently hosted a series of free webinars featuring experts and key opinion leaders from across the biopharma industry discussing the impacts of the #covid19 pandemic. Tune in on-demand here: citeline.com/resources/
-
Molecular Partners
@MolecularPrtnrs
We also announced today the submission of a manuscript to the research forum @biorxivpreprint detailing our #covid19 research to-date including preclinical potency, candidate design and in vivo data. Read the draft here: www.biorxiv.org/content/10.1101/2020.08.25.256339v1
-
Molecular Partners
@MolecularPrtnrs
Today we shared corporate highlights and unaudited financial results for the first half-year of 2020. Read more about our recent research and development efforts and key financials here: www.molecularpartners.com/molecular-partners-reports-corp…
-
Molecular Partners
@MolecularPrtnrs
Today we announced several advances for our anti-COVID-19 DARPin® program, including a new agreement with the Swiss Federal Office of Public Health @BAG_OFSP_UFSP and supportive in vivo data. #covid19 See more: www.molecularpartners.com/molecular-partners-announces-ag…
Molecular Partners
@MolecularPrtnrs
#covid19 is one of the biggest disease burdens in the world. Our tri-specific DARPin candidate, MP0420, offers a unique approach to tackling the virus by engaging up to 3 parts of the spike protein RBD simultaneously. Learn more: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
#meettheteam Daniel Steiner is our SVP of Oncology Research at Molecular Partners. Daniel is a valuable asset to our team and is responsible for building the department for DARPin® generation for all research pipeline projects. Learn more about us: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
Our novel multi-DARPin® approaches are ideally suited to block different escape pathways in tumors and reactivate standard of care therapies. See more about our approach: www.molecularpartners.com/our-approach/
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, we are driven to move the needle of medicine by building on deep trust, individual diversity and shared passion in order to reach our common goal of surmounting cancer’s toughest challenges. Learn more about our mission: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
Today we announced our collaboration with @AGCBiologics – securing clinical and commercial scale manufacturing to support the development of our novel tri-specific antiviral DARPin® program, MP0420, for #covid19. Read more: www.molecularpartners.com/molecular-partners-to-collabora…
-
Molecular Partners
@MolecularPrtnrs
Our MP0317 program is the second DARPin® protein in our immuno-oncology pipeline. It is designed to activate immune cells specifically in tumors and not in the rest of the body, potentially delivering greater efficacy with fewer side effects. Learn more: www.molecularpartners.com/pipeline/
-
Molecular Partners
@MolecularPrtnrs
Today we announced an update on abicipar with our strategic partner, Allergan. Read more: www.molecularpartners.com/allergan-an-abbvie-company-and-…
-
Molecular Partners
@MolecularPrtnrs
Activating immune cells is a powerful way to fight cancer. Our multi-DARPin® candidates can be engineered to activate immune cells preferentially in the tumor, thereby avoiding dose-limiting side effects and opening a new therapeutic window. Learn more: www.molecularpartners.com/our-approach/
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, we are developing custom-built DARPins® to solve clinical challenges other approaches can’t address. Learn more about our approach: www.molecularpartners.com/our-approach/
-
Molecular Partners
@MolecularPrtnrs
Today we shared preclinical data from our MP0317, MP0310 and Peptide-MHC #immunooncology DARPin programs during the virtual session of the American Academy of Cancer Research Annual Meeting #aacr20. More here: investors.molecularpartners.com/investor-and-scientific-d…
-
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, our work each day is informed by our purpose, vision, strategy, and our core.
Learn more about our values: www.molecularpartners.com/about-us/ -
Molecular Partners
@MolecularPrtnrs
Our DARPin® engine is a vast source of novel therapeutic designs based on the unique properties of this class of custom-built biologics. #biologics #biotech
Explore our pipeline: www.molecularpartners.com/pipeline/ -
Molecular Partners
@MolecularPrtnrs
Our new DARPin® therapeutic program for #covid19 targets up to three parts of the viral “spike” protein with one candidate. This approach could protect against drug resistance. Learn more: www.molecularpartners.com/molecular-partners-initiates-an…
-
Molecular Partners
@MolecularPrtnrs
It’s National Cancer Research Month, a cause close to our heart at Molecular Partners. We’re grateful to be part of a global community of researchers working to transform the lives of people with cancer. #ncrm20
-
Molecular Partners
@MolecularPrtnrs
We’re pleased to welcome three veteran U.S. biotech executives — Sandip Kapadia, Michael Vasconcelles, and Vito J. Palombella — to Molecular Partners’ Board of Directors.
-
Molecular Partners
@MolecularPrtnrs
Today we published our Interim Management Statement for Q1 2020, sharing updates on the continued progress of our immuno-oncology pipeline and recently published data from the abicipar program. More here: r.socialstudio.radian6.com/740396ef-89da-4892-857b-12891a…
-
Molecular Partners
@MolecularPrtnrs
We have identified multiple anti-COVID-19 DARPin® candidates that show ultra-potent neutralization of the live SARS-CoV-2 virus, and have chosen two to advance into in vivo testing against #covid19. Read more: r.socialstudio.radian6.com/32e1f061-6114-4c20-a50b-756ea2…
-
Molecular Partners
@MolecularPrtnrs
#dyk: Our CEO Patrick Amstutz has been on the company’s leadership team since our founding in 2004 — and Patrick was one of the team at University of Zurich that invented the DARPin® technology. Learn more about our team: www.molecularpartners.com/about-us/
-
Molecular Partners
@MolecularPrtnrs
Beating the #covid19 crisis will require all of our best efforts. Today we announced a new DARPin® therapeutic program: the first trispecific antiviral candidate for COVID-19. Initial data indicates potent neutralizing potential. Learn more: r.socialstudio.radian6.com/62aeccdd-4e0b-466e-878f-26f715…
-
Molecular Partners
@MolecularPrtnrs
We’ve pioneered a new class of medicines, DARPin® therapeutics. These small proteins show great potential to do what conventional biologics can’t. Dive into our science: www.molecularpartners.com/platform/
#biotech #darpin -
Molecular Partners
@MolecularPrtnrs
At Molecular Partners, our purpose is to transform the lives of people with #cancer and other serious diseases by delivering truly innovative therapies. Learn more about us: www.molecularpartners.com/about-us/ #biotech #darpin #biotherapies
-
Molecular Partners
@MolecularPrtnrs
Hello Twitter. In this challenging time it's important to communicate more than ever. Twitter gives us a new channel for timely updates in addition to sharing our work to advance DARPin therapeutics. Stay tuned. Stay well! #allinthistogether #biotwitter









































































































































































































































































































































































































